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Abstract 
Personalized medicine, also known as precision medicine, is a broad medical 
paradigm for tailoring patients’ treatments based upon their individual biological makeup 
to produce the most effective, safest clinical outcomes. Personalized medicine has the 
potential for enhancing nearly all fields of human health but has gained particular traction 
in oncology, a disease characterized by heterogeneity within patient populations. The 
application of personalized medicine in oncology requires both bioanalytical methods 
capable of providing real-time, useful clinical information in individual patients and new 
precision drugs matched to individual patient’s clinical disease.  My dissertation research 
encompasses two main projects centered on personalized medicine. The first project is 
the study of the molecular pharmacology of the antiviral and anticancer compound OSW-
1. OSW-1 induces its antiviral activity through targeting oxysterol-binding protein 
(OSBP) and its anticancer activity through targeting OSBP-related protein 4 (ORP4). My 
research has established ORP4 as a potential personalized drug target in ovarian cancer, 
and OSW-1 as a potential lead target with potent anticancer activity in ovarian cell lines 
through targeting ORP4. The second major development is a single cell mass 
spectrometry method capable of quantifying chemotherapy drug levels in individual 
cancer cells, including single cancer cells isolated from patients. These discoveries have 
clear potential for developing clinically relevant, better personalized medicine through 





Chapter 1: Introduction to Personalized Medicine 
1.1  Personalized Medicine as a New Paradigm in the Clinical Treatment of Human 
Disease  
Over the past few decades, an emerging amount of evidence have demonstrated 
the variability in drug responses between individuals.1 This differential reaction to 
medication between individual patients has initiated the realization of the importance of 
individual biological makeup in human medicine.1 The new movement in personalized 
medicine (also frequently referred to as precision medicine) encompasses a broad medical 
approach for tailoring patients’ treatments based upon their individual biological makeup 
to produce the most effective, safest clinical outcomes.1 In 2015, President Obama 
enacted the Precision Medicine Initiative with a mission to circumvent the “one pill treats 
all” approach through “enabling a new era of developing individualized care”. Although 
nearly all fields of human health could be enhanced through personalized medicine, 
oncology is particularly in need of personalized medicine approaches.2 Cancer is a disease 
characterized by extensive patient and disease heterogeneity2, and therefore, the “one pill 
treats all” approach to medicine is not suitable for cancer treatment. 
The field of personalized medicine grew out of the development of genomic 
sequencing technologies and the full sequence of the human genome in the early 2000s. 
Although only about 0.1% of the 3 billion bases pairs of DNA differ from person to 
person, these genetic differences are a significant cause of the different individual 
responses to clinical medicine.1 This understanding has introduced a new field of study 
called pharmacogenomics, which is a field of science determining how genetic variations 
in individuals affect their response to therapeutic intervention. Many different genes 
2 
could, in concert, contribute to individual drug responses, making identifying specific 
gene causing the responses difficult.3  A clear example of the genes that regulate a 
patient’s response to medicine are genes that code for cytochrome P450 (CYP 450) 
enzymes responsible for metabolizing, distributing, and excreting the vast majority of 
currently available drugs.4 Minute changes in the genes coding these enzymes, such as 
single nucleotide polymorphism (SNPs), could have pronounced effects on P450 
metabolism of drug compounds in individual patients.  
Although the “one pill treats all” approach for disease treatment still dominates 
modern medicine, recently many examples of therapies targeted to select populations of 
patients have been developed. Potentially the best example of existing precision 
medicines is the treatment of chronic myeloid leukemia (CLL) using the targeted drug 
Gleevec. 5 Most CLL cases arise from a chromosomal abnormality producing a BCR-
ABL1 fusion protein, which is only present in the CLL cells. 5 The Gleevec drug targets 
and inhibits the BCR-ABL1 enzyme, blocking the CLL cell proliferation.5 Many 
precision cancer drugs are monoclonal antibodies targeting cancer-specific cell surface 
protein, such as the drug Herceptin which targets the HER2 protein present in the cell 
surface of many breast cancer cells.6 
 
1.2 Current Practices in Clinical Bioanalytical Methods in Drug Administration   
Beyond the development of new precision therapeutics, a main obstacle halting 
the development of personalized medicine is the lack of bioanalytical technologies 
capable of providing clinically relevant information about an individual patient in real-
time. The absence of methods capable of guiding the personalization of drug 
3 
administration and treatment monitoring continues the “one pill treats all” approach to 
medicine, especially in the treatment of cancer.  Therapeutic Drug Monitoring (TDM) is 
the existing method used to monitor drug levels in patients.7 TDM is defined as a clinical 
laboratory technique of individualizing drug dosage through monitoring and maintaining 
plasma and blood concentrations within a therapeutic window.7 The advantages of TDM 
was established in the 1970’s when therapeutic ranges were established and the 
incidences of toxicity for digoxin, phenytoin, lithium, and theophylline could be 
reduced.8–10  Today, TDM is mostly performed on patient’s blood samples and quantified 
using a variant of immunobinding assay procedures such as fluorescent polarization 
immunoassay (FPIA), enzyme immunoassay (EMIT) or enzyme-linked immunosorbent 
assay (ELISA). 7,11,12 Although these assays produce quick results through commercial 
products, due to their antibody targeting methodologies, they are susceptible to cross-
reactivity creating falsely elevated drug concentrations.7,11,12   
The application of TDM is also hindered due to the vast degree of specialists 
needed to accurately administer a personalized treatment course.7 An interdisciplinary 
cohort of professionals consisting of scientists, clinicians, nurses, pharmacists, and 
analytical chemists are needed to work together to successfully administer an appropriate 
treatment course in a timely manner.7 Furthermore, a cost-effective methodology is 
needed to keep the price of treatment to a minimum.7 Because of these difficulties, the 
standard use of TDM is at a minimum in the clinical setting.7 
Current applications of TDM in oncology are further hindered due to the lack of 
personalization through not considering an individual’s unique cancer and drug uptake 
into the cancerous tumor cells. Because of an individual’s pharmacokinetic/ 
4 
pharmacodynamic capabilities, the drug concentration measured in the plasma may not 
predict the drug concentration in the tumor and tumor cells.13,14 Furthermore, tumor cells 
are a complex, heterogenous mixture of cells consisting of multidrug-resistant (MDR) 
cancer and non-cancer cells.15 These (MDR) cells can engage P-glycoprotein pumps to 
extrude drugs outside of the cells, further creating a difference in drug concentration in 
the tumor cells compared to the blood serum.16 A bioanalytical method capable of 
quantifying drug compound in individual cancer cells in a time efficient and non-invasive 
manner would prove a valuable personalized tool for assessing individual TDM.  
 
1.3 The Oxysterol-Binding Proteins (OSBP/ORPs) As Potential Precision Drug 
Targets for Antiviral and Anticancer Drug Development  
Oxysterol-binding proteins (OSBP) and OSBP-related proteins (ORPs) comprise 
a family of proteins conserved in all eukaryotes, from yeast to humans.17,18 OSBP, the 
OSBP/ORP member first identified, was discovered as a high affinity binder of oxysterols 
in vitro. 19,20 Oxysterols are 27-carbon products of cholesterol oxidation, mainly 
performed by hepatic cytochrome P450 enzymes (Figure 1, 25-hydroxycholesterol (1) 
as an example oxysterol).4  
Oxysterols have a variety of biological activities including: inducing cytotoxicity, 
cholesterol regulation, and membrane integrity perturbation.21–26 Although the biological 
role of the individual member of the OSBP/ORPs are not completely elucidated, an 
overall idea is that these proteins are involved in cellular lipid sensing or transport, 
including sterols, and the preferential binding to oxysterols of the OSBP/ORP could 
control lipid homeostasis or specific cellular signaling events.17,27–30  
5 
 The OSBP/ORP protein family shares a conserved carboxy-terminal ligand 
binding domain (LBD) also referred to as OSBP related domain (ORD). The ORD 
structure consists of 19 anti-parallel beta sheets based upon protein structures of yeast 
homologs (Figure 2).18,31  Outside of the ORD, the N-terminal ~50 kDa contains two 
phenylalanines in an acidic tract (FFAT) domain and an amino terminal pleckstrin 
homology (PH) domain (Figure 2).18  The OSBP PH domain is reported to interact with 
phosphotidylinositols in cell membranes, specifically PI4P and PI2P, for trans-Golgi 
localization.32,33 The FFAT motif is able to interact with the ER resident vesicle-
associated membrane proteins (VAPs) providing a tether between OSBP and the ER.34 
 
OSBP Biology  
OSBP has been reported to bind to 25-hydroxycholesterol with a much higher 
affinity than cholesterol. 17,23,35–37 OSBP is also reported to bind phosphatidylinositols 
with unclear affinity. 17,23,35–37 OSBP is reported to be located at the Golgi/endoplasmic 
reticulum (ER) membrane contact site (MCS), where it traffics cholesterol from the ER 
to the Gogi, while retroactively trafficking phosphatidylinositol 4-phospate (PI4P) from 

















































produced by the phosphorylation of phosphatidylinositol by PI4KIIIβ kinase at the Golgi 
and the hydrolysis of PI4P by SAC1 on the ER membrane.17,30 OSBP mediates this 
transfer keeping the concentration gradient intact in both organelle membrane.40 Further 
studies also suggested that OSBP is able to recruit CERT to the Golgi-ER interface for 
ceramide transport and sphingomyelin production. In this model,  PI4KIIIβ is stimulated 
to increase   PI4P production, producing another level of lipid regulation at cellular 
membranes.41  
Phosphorylation of OSBP by Protein kinase D (PKD) inactivates OSBP by 
masking the PH domain and inhibiting the translocation of OSBP to the Golgi.42 
Furthermore, PKD can activate and inhibit PI4KIIIβ and CERT, respectively.42 This leads 
to a potential mechanism of action of OSBP where PKD phosphorylation of PI4KIIIβ 
leads to increased PI4P in the Golgi and recruitment of OSBP through its PH domain and 
 








activation of ARF1. This leads to more production of PI4P and recruitment of CERT to 
the MCS. OSBP’s transportation of cholesterol from the ER to the Golgi and counter 
transport of PI4P from the Golgi to the ER leads to CERT shutting ceramide leading to 
Sphingomyelin (SM) production. Together, this represents a lipid homeostasis 
mechanism controlled by PKD phosphorylation.42  
OSBP is reported to regulate ERK1/2 signaling activity through modulating the 
activity of phosphatases that regulate ERK.43 In this model, OSBP is believed to be a  
scaffold protein for the tyrosine and serine/threonine phosphatases, HePTP and PP2A, 
and the OSBP/phosphatase activity is controlled by sterol binding to OSBP. Under 
normal cholesterol level conditions or the absence of oxysterols, OSBP is bound to 
cholesterol and undergoes a conformation change masking the PH domain, producing an 
inactive phosphatase complex, which keeps ERK1/2 activity repressed. Upon low 
cholesterol levels or oxysterol binding, the conformation of OBSP is changed, unmasking 
the PH domain, removing the phosphatases, translocating OSBP to the Golgi to replenish 
cholesterol levels and thereby activating ERK1/2 signaling activity.43   
An additional study found that OSBP interacts with JAK2/STAT3 signaling 
leading to the expression of profilin-1.44 In this model, 7-ketocholesterol leads to the 
production of profilin-1 through STAT3 activation by JAK2 and OSBP. Upon OSBP 
binding with 7-ketocholesterol, OSBP interacts with JAK2 and becomes phosphorylated 
leading to STAT3 interacting with OSBP/JAK2. STAT3 is then able to translocate to the 
nucleus to induce transcription of profilin-1.44 This demonstrates another example of 
OSBP acting as a lipid sensor regulating signaling in the cells. 
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Recently, OSBP was discovered to be required for the replication of dozens of 
currently untreatable human pathogenic RNA viruses, including members of the 
Enterovirus genus of viruses, Zika virus, Dengue fever virus, and hepatitis.45–48   
  
ORP4 Biology 
ORP4, the most similar family member to OSBP, shares none of OSBP’s 
biological regulation or cellular localization.36,49Unlike the ubiquitous tissue expression 
of OSBP, ORP4 is selectively expressed in a limited amount of normal tissues including 
the brain, retina, and testes.50 Of importantance, the ORP4 protein has recently been 
demonstrated to be essential for cancer cell proliferation in immortalized cell lines, and 
essential for cellular proliferation in T-cell acute lymphoblastic leukemia (T-ALL) 
patients.51,52 ORP4 is reported to promote mitochondrial respiration in  immortalized 
immune cells by regulating calcium release from the endoplasmic reticulum through 
mediating a G-protein activation of PLC3β.51 Knockdown of ORP4 in cancer cell lines 
results in increased apoptosis, autophagy, and mitochondrial dysfunction, which 
phenocopies OSW-1 treatment.51,53–57 The limited, selective expression of ORP4 in 
normal tissue while being essential for cancer proliferation, signifies ORP4 as a potential 
cancer precision therapeutic target. 
 
1.4 The Antiviral and Anticancer Compound OSW-1 Targets OSBP and ORP4  
The natural product OSW-1 (3β,16β)-3,17-Dihydroxy-22-oxocholest-5-en-16-yl-
2-O-acetyl-3-O-[2-O-(4-methoxybenzoyl)-β-D-xylopyranosyl]-α-L-arabinopyranoside) 
is a potent anticancer compound isolated from the bulbs of the  Ornithogalum saundersiae 
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plant. 58–60  OSW-1 and other OSBP-targeting compounds were found to have broad-
spectrum antiviral activity against many different RNA viruses.61–64 In addition to its 
antiviral activity, the OSW-1 compound has potent anticancer activity through putatively 
binding OSBP-Related Protein 4 (ORP4).51,54–56,60 OSW-1 treatment induces the 
degradation of cellular OSBP and ORP4. 60   
 
1.5 Single Cell Bioanalytical Methods for Potential Use in Personalized Medicine  
The development of single-cell mass spectrometry methods has been a major 
focus in bioanalytical research.65 These analytical methodologies have investigated 
heavily on the “omics” of individual, single cells discovering which genomic, 
transcriptomic, proteomic, and metabolic changes trigger oncogenic progression, rather 
than drug quantification.66–68 Mass spectrometry is becoming the dominant technology 
for single-cell metabolite analysis due to its low sample preparation, high sensitivity, and 
high-throughput, label free ability. Multiple mass spectrometry ionization techniques 
(e.g. matrix assisted laser desorption/ionization (MALDI)65,69–71, electrospray ionization 
(ESI)72–75, electron ionization (EI)76) coupled with numerous mass analyzers (e.g. time of 
flight (TOF), quadruple, Orbitrap) have been successful for the analysis of metabolites 
from single cells. The techniques broadly fall under two categories, ambient ionization or 
non-ambient ionization. MALDI is a well-established, commonly utilized, non-ambient 
technique used for detecting and quantifying metabolites from single cells.68,77 Due to the 
soft ionization, molecules remain intact, ideal for metabolomic analysis. MALDI, 
however, requires fixation of cells on a solid matrix and the use of a vacuum, resulting in 
the lack of analyzing live cells and the addition of interfering MALDI Matrix with the 
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small weight metabolites (<500 daltons).67 Due to this, the development of ambient 
techniques has been the preferred method development to analyze live, single cells 
resulting in near native environment of the cells.  
Ambient ionization techniques can be broadly grouped into either laser 
desorption/ionization or microprobe extraction methods. Laser desorption/ionization 
methodologies have been used to mainly study embryos but have also been utilized to 
perform in situ metabolomic analysis of individual, single cells including oocytes, plant 
cells, and mammalian cells.78–81 Microprobe extraction methodology stems from the 
initial live-video single cell mass spectrometry technique from Masujima’s lab.82 These 
methods take advantage of analyzing the metabolites of individual, live cells either 
through the use of a probe that penetrates the cells capable of analyzing sub-cellular 
compartments, or a larger probe capable of lysing the entire cell. Furthermore, multiple 
separation techniques (e.g., capillary electrophoresis, ion mobility) are able to be coupled 
to these methods and applied on the single cell level.66,83 
 
The Single-Probe as a Personalized Drug Monitoring Method 
 The Single-Probe is a developed sampling and ambient ionization device designed 
by the research group of Prof. Zhibo Yang in the Dept. of Chemistry and Biochemistry 
at the University of Oklahoma.84 The Single-Probe is a microprobe extraction mass 
spectrometry technique uniquely capable of analyzing live, single cells with little to no 
sample preparation in real time.84 It consists of a dual-bored quartz tubing with a sharp 
tip (<10µM) capable of a continuous flow of ionized solvent.84 Once the Single-Probe is 
in contact with a single cell, the solvent flows through the tip, creates a micro lysis of the 
11 
cell and forms a liquid junction.84 The cellular contents are extracted toward the nano-
ESI emitter and ionized for MS analysis.84 
 The Single-Probe MS technique has been modified and utilized for multiple 
applications, including MS imaging (MSI) analysis of multicellular spheroids, and 
detection of intracellular compounds from algal and adherent mammalian cells.85–89  
 
1.6 Summary of Dissertation Research: New Precision Compounds Targeting OSBP 
and ORP4 and New Single Cell Mass Spectrometry for Chemotherapy Drug 
Administration  
The development of clinical cancer personalized medicine is limited by: 1)  the 
lack of precision drugs and therapies that target cancer specific protein targets identified 
in individual patient’s cancer; and 2) the lack of clinical bioanalytical methodology 
capable of personalizing the administration of chemotherapy drugs to ensure the most 
effective outcomes in the individual patients. To address this dilemma, my dissertation 
research encompasses the study of OSBP and ORP4 as druggable targets for the 
 
 
Figure 3: Research Dissertation Schematic. Development of OSW-1 for antiviral/ 















development of new antiviral and anticancer drug therapeutics. Further, I have worked to 
develop new applications of the single cell mass spectrometry technology to measure of 
the intracellular drug levels in single cancer cells from patients.  
The three major projects of my doctoral research included in this dissertation are: 
1) determining the prophylactic antiviral activity of the OSW-1 compound through 
targeting OSBP (Chapter 2); 2) characterizing ORP4 as a precision cancer target in 
ovarian cancer and OSW-1 as a potential precision cancer drug through targeting ORP4; 
(Chapter 3), and; 3) development of single cell mass spectrometry application for the 
quantification of drugs in individual cancer cells isolated from patients undergoing 














Chapter 2: Molecular Pharmacology of Antiviral Compound 
Targeting OSBP, Including OSW-1 
 
Abstract 
Oxysterol-binding protein (OSBP) is a conserved lipid regulator and lipid 
transport protein essential for the replication of several classes of RNA pathogenic 
viruses, including the Enterovirus genus of viruses. These RNA viruses that use OSBP to 
replicate in cells are responsible for many untreatable human diseases. Our research group 
has studied the molecular pharmacology of antiviral small molecules targeting OSBP, 
especially the natural product compound OSW-1. We’ve identified that the OSW-1 
compound is a potent inhibitor of enterovirus replication in vitro through binding and 
degradation of the OSBP protein. We have shown that a short-term exposure (i.e., 1- 6 h) 
at a low dose (i.e., 1 nM) results in a long-term reduction of the OSBP protein for up to 
72 hours with no changes in cellular viability, morphology, or proliferation, but correlates 
with the inhibition of viral replication. This multiday, multigeneration repression of the 
OSBP protein is independent of residual OSW-1 compound remaining in cell, nor is it 
caused by transcription inhibition, proteasome degradation, calpain activity, or 
autophagy. This long-term reduction and repression of OSBP presents a new opportunity 
for broad spectrum anti-Enterovirus activity, and a new route for prophylactic treatment 
through targeting of a host protein. We have also studied the molecular pharmacology of 
other reported antiviral compounds that target OSBP, including the steroidal compound 
T-00127-HEV2 (THEV2). I am co-author on both papers from our research group 
studying the molecular pharmacology of OSBP-targeting antiviral compounds, and my 
individual experimental research contributions to this overall published research project 
are reported here.  
 
Allocation of Contribution 
 This chapter is a partial recapitulation results from two published articles: the 
2018 ACS Chemical Biology paper90 and the 2019 Antiviral Research paper.45 The 
published articles was created from a group effort and has many co-authors, the major 
contributors were myself, Dr. Brett Roberts, and Mr. Zachary Severance. In this 
dissertation chapter, I have included only results from this paper that I produced, with the 
exception of the antiviral experiments (Figure 13), which were produced by our 
molecular virology collaborator Prof. Earl Blewett at Oklahoma State University Center 
of Health Sciences. The binding experiments (Figure 4, Figure 11) were jointly 
performed between myself and Mr. Zachary Severance. Furthermore, all mass 
spectrometry data acquisition was conducted through our established collaboration with 
the research group of Prof. Zhibo Yang lab at the University of Oklahoma. I worked with 
Dr. Shawna Standke, a graduate student in the Yang lab, to produce the mass 
spectroscopy results in Figure 6, Figure 7, Figure 8, and Figure 9. The mass 
spectroscopy studies used the deuterated version of the OSW-1 compound produced by 




OSBP is a required non-enzymatic host protein for the broad replication of  the 
Enterovirus genus of virus responsible for many untreatable illnesses including: the 
common cold, acute respiratory infections, pneumonias, myocardial infections, hand, 
foot, and mouth disease, acute hemorrhagic conjunctivitis, and the paralytic condition 
acute flaccid myelitis.91–94 In addition, OSBP is known to be essential for hepatitis C 
virus, encephalomyocarditis, dengue, and zika virus replication.48,95,96 These viruses 
replicate in the cytosol of host cells through the hijacking of host proteins to produce 
replication organelles (RO).97 RO are membrane bound structure made by stealing the 
membrane components of host ER and Gogi organelles.98–102 The human OSBP protein 
is reported to be critical for the formation of RNA virus’s replication organelle 
formation.46 For example, the enteroviral 3A protein recruits host ARF1 and GFB1 
protein to the RO, in turn recruiting PI4KIIIβ and leading to PI4P accumulation. OSBP 
is able to localize to the RO through its interactions with PI4P and ARF1, and presumably 
shuttles essential cholesterol to the RO similar to its endogenous function between the 
Golgi and ER.100–102  
 The essentiality of the OSBP protein for viral replication has led to the 
development of multiple OSBP targeting compounds for antiviral development. OSBP 
has been identified as the cellular target of the anti-enteroviral compounds, TTP-8307 
(TTP)62, the FDA approved antifungal itraconazole (ITZ)64, the steroidal compound T-
00127-HEV2 (THEV2)63, and the anti-cancer compound, OSW-161. ITZ is a promiscuous 
compound with multiple cellular targets showing anti-fungal, cancer, and viral 
activity.103–105 It’s broad range antiviral activity is believed to occur through its reported 
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binding to OSBP (Kd of 430 nM) which alters its cellular localization and inhibits 
cholesterol and PI4P counter transport.64 TTP-8307 was also demonstrated to inhibit 
OSBP trafficking and to change the cellular localization of the protein.48 THEV2 similar 
to both ITZ and TTP also changed the localization of OSBP and inhibited the transfer 
function.63 Furthermore, THEV2 showed increased antiviral activity upon OSBP 
knockdown.63 OSW-1 is unique compared to the other OSBP-targeting compounds as it 
targets both OSBP and ORP4, and that OSW-1 treatment caused a unique proteasomal 
degradation of OSBP.60  OSW-1’s broad antiviral activity is correlated to OSBP binding 
and perturbation rather than ORP4 binding.46,64  
Herein, this chapter describes my contributions to the identification of OSW-1 as 
a broad-spectrum prophylactic compound that works through a non-toxic, selective, and 
long-term degradation of the host OSBP protein. I show that the multiday repression of 
OSBP is independent of residual OSW-1 compound present in the cell. I also shown that 
the OSBP repression is not due to OSBP cleavage by activation of calpain protease 
activity. Further, my results demonstrate that the other OSBP-targeting antiviral activity 
THEV2 binds at an overlapping site to OSW-1, but unlike OSW-1, THEV does to induce 
the repression of OSBP in cells. My research contributions have clear applications for 





2.2.1 Cell Lines and Viruses 
HCT116 (ATCC CCL-247) colon cancer cell line was cultured in McCoy 5A 
media (Thermo 16600108) supplemented with 10% Hyclone and 1% penicillin 
streptomycin. HEK293 embryonic kidney cell line was cultured in DMEM (Thermo 
11995073) supplemented with 10% Hyclone (Fisher Sci SH3006603) and 1% penicillin-
streptomycin (Thermo 15140122). K-562 (ATCC CCL-243) was cultured in RPMI 1640 
(Thermo 22400105) media supplemented with 10% Hyclone and 1% penicillin 
streptomycin. Coxsackievirus A9 (strain CoxA9-01) and Echovirus 2 (strain Echo2- 01) 
were obtained from the Oklahoma State Department of Health Laboratory. They are 
clinical isolates, obtained from OK residents and typed by the OK State Department of 
Health and/or the Center for Disease Control and Prevention. All other identifiers have 
been stripped off. These viruses were passaged twice in RD cells, aliquoted in 1.0 mL 
amounts and stored in complete medium at -80 ⁰C. Each virus was titered on RD cells 
using a TCID-50 assay1 . To allow m.o.i. to be determined a conversion factor of 0.7 was 
used to change TCID-50 to pfu/ml. 
 
2.2.2 Cell Lysis 
Adherent cells were lysed by aspiration of media, wash with 1X PBS, addition of 
TrypLETM Express (Gibco 12605- 010), and neutralized through the addition of media. 
Cells were spun at at 14,000 RCF for 0.45 min at 4C. Supernatant was aspirated, cell 
pellet washed with 1X PBS, and resuspended in 50 µL of AC lysis buffer (150 mM NaCl, 
1.5 mM MgCl2, 5% glycerol, 0.8% NP40, 1mM DTT, 50 mM HEPES, 25 mM NaF, 1 
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mM Na3PO4) with 3X HALT/EDTA protease inhibitor (Thermo 78438) and 0.2 mM 
phenylmethanesulfonylfluoride (Goldbio). Cells were freeze/ thawed (X3) with LN2 and 




SDS-PAGE gels (8.5%) were loaded with 25 µg of protein, transferred to 
nitrocellulose membrane ((Bio-Rad 1620115) with a constant voltage of 100V for 1 h at 
4C. The membrane was blocked in 5% milk for 0.5 h. Following washing with TBST 
(X3), the membrane was incubated with 1:500 ORP4 antibody (Santa Cruz sc-365922) 
or 1:1000 OSBP antibody (Santa Cruz sc-365771) overnight at 4C. Following washing, 
the membrane was incubated with 1:3000 Secondary antibody (Santa Cruz sc-2060) for 
1 h at RT. Following washing, the membrane was developed with ClarityTM Western 
ECL substrate (Bio-Rad 1705061) and imaged on the Bio-Rad ChemiDocTM Touch 
Imaging System. The membrane was incubated with 1:1000 β-actin HRP (Santa Cruz sc-
47778 HRP) after washing and developed as previously described.  
 
2.2.4 OSW-1 Compound Washout Treatments 
Cells were treated with 1 nM OSW-1, 1 nM Taxol, or DMSO media for 6 hr or 
the indicated time period. Media was removed and the cells were gently washed with 5 
mL of complete media 3 times and then 10 mL of fresh, OSW-1-compound free media 
was added back to the cells. The cells were then allowed to recover for the indicated times 
(0-72 hrs) and were lysed as described above and analyzed by Western blot.  
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2.4.5 Deuterated OSW-1  
The deuterated OSW-1 analog (Fig. 1A, 2) was produced via total synthesis of 
OSW-1 adapted from literature procedure. During the synthesis of the xylose component, 
a benzoate group containing the deuterated methyl substituent was introduced. 1H NMR 
(400 MHz, Acetonitrile-d3) δ 8.02 (d, J = 9.0 Hz, 2H), 7.02 (d, J = 8.9 Hz, 2H), 5.31 (d, 
J = 4.9 Hz, 1H), 4.84 (t, J = 8.2 Hz, 1H), 4.73 (dd, J = 8.3, 6.2 Hz, 1H), 4.61 (d, J = 7.7 
Hz, 1H), 4.20 (s, 1H), 4.01 (d, J = 6.2 Hz, 1H), 3.92 (dd, J = 11.5, 4.9 Hz, 1H), 3.88 (s, 
1H), 3.76 (dd, J = 12.4, 4.2 Hz, 1H), 3.67 (dt, J = 8.2, 4.2 Hz, 2H), 3.64 – 3.50 (m, 2H), 
3.42 (dd, J = 12.4, 2.3 Hz, 1H), 3.38 – 3.22 (m, 2H), 2.86 (q, J = 7.3 Hz, 1H), 2.69 (s, 
1H), 2.46 (ddd, J = 18.2, 9.0, 6.5 Hz, 1H), 2.23 – 2.08 (m, 5H), 1.99 – 1.90 (m, 1H), 1.85 
– 1.76 (m, 1H), 1.75 – 1.68 (m, 2H), 1.67 (s, 3H), 1.64 – 1.38 (m, 5H), 1.32 (dt, J = 13.1, 
6.6 Hz, 1H), 1.29 – 1.14 (m, 3H), 1.07 (d, J = 7.4 Hz, 3H), 1.04 – 1.01 (m, 1H), 1.00 (s, 
3H), 0.94 – 0.83 (m, 1H), 0.82 – 0.74 (m, 9H). 13C NMR (101 MHz, Acetonitrile-d3) δ 
220.09, 169.95, 165.66, 164.73, 142.44, 132.79, 123.64, 121.86, 114.81, 102.92, 100.98, 
88.19, 86.20, 80.82, 75.74, 74.47, 71.90, 71.72, 70.49, 67.67, 66.46, 65.22, 50.89, 49.20, 
46.94, 46.54, 43.07, 39.71, 38.13, 37.35, 35.74, 33.19, 32.86, 32.69, 32.63, 32.37, 28.19, 
22.88, 22.67, 21.34, 21.04, 19.79, 13.56, 12.16. HRMS calcd for C47H65D3O15Na: 
898.4639 [M + Na]+, found 898.4611. 
 
2.2.6 OSW-1 Quantification  
LCMS: HCT-116 cells (1.5x105) were seeded in a 6-well plate. Upon 60% 
confluency, cell lysate was created following a 1 hr treatment of 100 nM OSW-1, with or 
without a 24 hr post wash recovery. Trypsin (0.5 mL) was used to detach the cells, with 
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additional McCoy’s media (0.5 mL) to stop digestion. Cell count was performed using a 
Bio-Rad TC20TM Automated Cell Counter with trypan blue viability staining. Cells were 
spun at 500 xg for 5 min followed by a 1-mL PBS wash. The cell pellet was lysed using 
1 mL of 50 nM d-OSW-1 dissolved in cold acetonitrile and methanol (1:1) with brief 
vortexing on ice for 10 min. The cell pellet was spun at 15000 xg at 4°C for 15 min. The 
supernatant was transferred to a new tube and dried using a speed vacuum (Savant 
SPD11V, Thermo Scientific) at 70°C. Prior to analysis, cells are resuspended in 150 µL 
of ACN: H2O (1:10). Analysis was performed using a Waters nanoAQUITY BEH C-18 
column (100 µm x 100 mm, 1.7 µm) coupled with a mass spectrometer (Thermo LTQ 
Orbitrap XL, Waltham, MA) using a flow rate of 0.3 uL/min. Mobile phase A is ACN 
with 0.1% formic acid, and mobile phase B is H2O with 0.1% formic acid. The time/%A 
are as follows: 0/0, 1/50, 2/100, 3/100, and 4/0 for a total runtime of 5 minutes. 
SCMS: HCT-116 cells (1.5x105 ) were seeded on to a glass microchip (18 mm diameter) 
with chemically-etched microwells (55 µm diameter; 25 µm deep) placed into each well 
of a 6-well plate. Upon 60% cell confluency, cells were treated as described for nano-
UPLC/MS. Following treatment, the microchip was washed with 5 mL of FBS-free 
McCoy’s media and placed on an X, Y, Z-translational stage for quantification. MS 
analysis was performed as previously described.4 Briefly, singleprobes were coupled to 
the mass spectrometer by using a flexible arm clamp to position the nano-ESI emitter in 
front of the inlet. The solvent-providing capillary was connected to the solvent through 
the conductive union. For quantification, 50 nM d-OSW-1 was added into the solvent. 
High voltage (~4.5 kV) was used for SCMS experiments in the positive ion mode with a 
mass resolution (m/∆m) of 60,000. A flow rate of ~5 nL/s was used (the actual flowrate 
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is optimized for each Single-probe). Data was collected using Xcaliber software and 
exported into Excel for analysis. 
 
2.2.7 Calpain Analysis 
For the continual treatment, HeLa cells were seeded out in a 6 well plate. Upon 
70% confluency, cells were treated with DMSO, DMSO and ALLN (10µM), OSW-1 
(1nM), or OSW-1 (1nM) and ALLN (10µM) for 24 hr. Cells were lysed and analyzed 
following the 6-well lysis method and the western blot protocol. Under the washout 
experimental conditions, cells were treated with DMSO or OSW-1 (1nM) for 6 hr. Cells 
were washed out according to the washout experimental method. After 24 hr recovery, 
one set of DMSO and one set of OSW-1 was lysed following the 6 well lysis method. At 
the same time (24hr post-wash), ALLN (10µM) was added to one set of DMSO and one 
set of OSW-1. The cells continued to incubate until 48 hr post-wash, at which point they 
were lysed and analyzed using the western blot method. 
 
2.2.8 Antiviral Analysis 
Antiviral assays were done in the research group of Prof. Earl Blewett at 
Oklahoma State University Center for Health Sciences (OSU-CHS). HeLa cells were 
grown to <75% confluency (healthy log phase cells) in complete media, DMEM (Hyclone 
SH30081.0) with 10% FBS (Atlanta Biological S11550) and 1% penicillin-streptomycin 
(Gibco 15140-122). For experiments, cells were trypsinized, counted using a 
hemocytometer and seeded into 20 wells of two 24-well trays (Falcon 3047) with 2.0 x 
105 cells per well, in 1.0 mL complete media. Each treatment is performed using 
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quadruplicate wells (n=4) and each virus was on a separate plate. After seeding, cells 
were incubated 20 hr at 37 ºC, 5% CO2, at which point cells have grown to a near 
confluent monolayer. For the OSW-1 compound continual treatment experiments, (Fig. 
6A), the media was gently removed from each well, and 1mL of media was added with 
the desired OSW1-compound concentration to each well, without disturbing the cells. 
Cells were incubated for 6 hr, after which time the media was removed and cells were 
gently washed three times with 1.0 mL of FBS-free DMEM media. After the media was 
removed, CoxA9-01 or Echo2-01 viruses, diluted in serum-free DMEM with a M.O.I. of 
1.0 was added to the culture. The 2.0 x 105 cells per well was assumed to double during 
incubation so 4.0 x 105 pfu/well of virus was used for an M.O.I. of 1.0. The virus and 
cells were incubated for 30 minutes at 37 ºC 5% CO2. Then, the virus inoculum was 
removed, and the culture washed one time with 1.0 mL of serum-free media per well. 
Then, 1.0 mL of complete media with the indicated concentration of OSW-1 was added 
to the well, and the infected cells were then incubated for 10 hr at 37 ºC, 5% CO2. After 
10 hrs the plate was stored at -80 ⁰C until the TCID-50 titration. This experiment was 
performed independently three times to generate the data in the figure. For the OSW-1 
compound washout treatment experiments, cells were seeded as above. After 20 hr 
incubation the media was gently removed from each well, and 1mL of media was added 
with the desired OSW-1-compound concentration to each well, without disturbing the 
cells. Cells were incubated for 6 hr, after which time the media was removed and cells 
were gently washed three times with 1.0 mL of FBS-free DMEM media. This was 
replaced with complete media and cells allowed to incubate for 20 hrs. After the media 
was removed, CoxA9-01 or Echo2-01 viruses, diluted in serum-free DMEM with a 
22 
M.O.I. of 1.0 was added to the culture. The 2.0 x 105 cells per well was assumed to double 
and double again during incubation so 8.0 x 105 pfu/well of virus was 14 used for an 
M.O.I. of 1.0. The virus and cells were incubated for 30 minutes at 37 ºC 5% CO2. Then, 
the virus inoculum was removed, and the culture washed one time with 1.0 mL of serum-
free media per well. Then, 1.0 mL of complete media was added to the well, and the 
infected cells were then incubated for 10 hr at 37 ºC, 5% CO2. After 10 hr incubation, the 
plate was stored at -80 ⁰C until processing. Then, the plates were rapidly thawed, the cells 
in media were scrapped from the wells into sterile 1.5 mL centrifuge tubes and the 
suspension then centrifuged at 10,000 g at 4⁰C to produce the virus containing 
supernatant, which is assayed for TCID-50 titration on sub-confluent RD cells. This 
experiment was performed independently three times to generate the data in the figure. 
 
2.2.9 Competitive Binding Assay  
OSBP and ORP4L were cloned into pcDNA 3.1 vector. ORP4L contained a Myc-
His tag, whereas OSBP did not. The vectors were transfected into HEK-293T cells with 
lipofectamine 2000. Following a 48 hr incubation, cells were lysed with M-per-HALT 
with EDTA. Protein lysate was isolated through ultracentrifugation at 100,000g for 1 hr. 
Lysate was diluted to a working concentration of 0.2 mg/ mL The lysate was incubated 
with [3H] 25-OHC at 4 °C for 16 hr followed by a 30 min RT incubation with charcoal 
dextran and centrifuge for 15 min at 1,900 g. The cleared lysate was added to scintillation 





2.3.1 OSW-1 Treatment Selectively Degrades OSBP in Cells 
The OSW-1 compound (Figure 5) is known to bind to both OSBP and ORP4 with 
high affinity (Figure 4) and induce degradation of OSBP.60 I also showed that OSW-1-
induced degradation of OSBP in HCT-116 cells in a time time-dependent manner (Figure 
5B). An OSW-1 treatment of 1 nM induced a rapid reduction in OSBP levels, starting at 
4 hours of treatment, until ~90% of OSBP had been reduced at after 24 hours treatment. 
Interestingly, I showed for the first time that although ORP4 levels were also reduced 
upon 1 nM OSW-1 treatment, the reduction of ORP4 levels were much slower and less 
significant, leading to only a ~50% reduction of ORP4 after 24 hours treatment (Figure 
5B).  
Having established the OSW-1-induced reduction of OSBP, experiments were 
then performed to determine how quickly OSBP levels returned to normal levels once 
OSW-1 treatment stopped. These ‘washout experiments’ were performed through 
 
Figure 4: OSW-1 competitive binding to the human OSBP and ORP4 protein 





treating the cells with 1 nM of OSW-1 for 6 hours,  followed by removal of the 
compound-containing media, washing the cells with fresh media three times, and then 
incubating the cells several days in OSW-1 free media. The washout experiment showed 
that 1 nM, 6 hr treatment induced a ~90% reduction of OSBP that remained reduced   for 
72 hours after compound treatment stopped (Figure 5C).   This response is selective only 
to the OSW-1 compound and not due to a cytotoxic event (e.g., taxol treatment). for up 
to 72 hr (Figure 5C).  
This repression of OSBP upon washout conditions is shown to be both 
concentration and time dependent in HCT-116 (Figure 5D-F). Treatments as short as  1 
hour with 1 nM transient treatment of OSW-1 is sufficient to induce the 90% reduction 
in OSBP levels 24 hours later (Figure 5D), and a 30 min 1 nM OSW-1 treatment induces 
a partial reduction of OSBP (Figure 5E).  Furthermore, as little as 0.5 nM OSW-1 for 1 
hr is capable of producing significant degradation and repression of OSBP at 24 hours 
post-washout. (Figure  5E). Multiple other cells lines treated with low-dose, transient 
OSW-1 concentration showed similar long term reduction in OSBP levels.90 
 
2.5.2 OSBP Repression is Independent of Residual OSW-1.  
Mass spectrometry quantification was used to determine if the long term (Figure 
5C) repression of OSBP is due to residual intracellular OSW-1 remaining post-washout.  
A liquid-chromatography mass spectrometry (LCMS) analysis was first performed on 
cellular lysate from OSW-1-treated HCT-116 cells. Cells were treated with 100 nM 
OSW-1 for 1 hr, compound-containing media was removed, the cells were washed three 
times and incubated in compound-free media for either 0 hr or 24 hr. An internal standard 
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Figure 5: OSW-1 degrades the OSBP protein in a time and concentration dependent 
manner in HCT-116 cells  A) The OSW-1 molecule. B) OSBP and ORP4 Western 
blot following 1 nM OSW-1 treatment. C) A 6 h treatment of compound, followed 
by 3X wash and Western blot at the provided times. D) 1 nM OSW-1 treatment for 
the indicated time followed by 24 h recovery. E) 1 nM OSW-1 treatment for the 
indicated time followed by 24 h recovery. F)  1 hr treatment at indicated OSW-1 




of deuterated OSW-1 added to the lysate in order to quantify the amount of OSW-1 
compound present in the lysate. Following the 1 hr treatment, an OSW-1 intracellular 
concentration of 1.74 ± 0.74 μM was measured (Figure 6, Figure 8). However, following 
24 hr recovery post-washout, the OSW-1 compound was undetected (Figure 6, Figure 
8). Furthermore, a complementary analysis using the Single-Probe single cell mass 
spectrometry technology developed by our collaborator, Dr. Yang, was used to validate 
the LCMS results.84 The ability of the Single-probe system to detect intracellular OSW-
 
Figure 6: Liquid Chromatography Mass Spectrometry (LCMS) quantificaiton of 
OSW-1 at 0 h and 24 h post washout of a 100 nM treatment for 1 h. The deuterated 





1 in single cells has been previously demonstrated.84 In individual HCT-116 cells, the 
OSW-1 compound was detected following the 1 hr treatment but was not detected 
following a 24 hr recovery after washout (Figure 7, Figure 9). Together, this suggests 
that the OSBP repression is independent of prolonged intracellular amounts of  the OSW-
1 compound.  
 
 
Figure 7: Chromatogram of LCMS quantificaiton of OSW-1 (m/z 895.44) at 0 h and 
24 h post washout of a 100 nM treatment for 1 h. The deuterated OSW-1 analog (m/z 





2.3.3 OSBP Repression is independent of Calpain activity  
The OSW-1 compound has been shown to influence calcium regulation in 
lymphoblastic leukemia cells.57 Because of this, I tested if the calcium-activated protease 
calpain could be responsible for the long-term repression of OSBP upon OSW-1 
 
Figure 8: Single Cell Mass Spectrometry (SCMS) quantificaiton of OSW-1 at 0 hr 
and 24 hr post-washout of a 100 nM treatment for 1 hr. The deuterated OSW-1 






treatment. Co-administration of the calpain inhibitor ALLN at 10 µM with 1 nM of OSW-
1 in HEK-293 cells did prevent the initial degradation of OSBP, but addition of the ALLN 
inhibitor in cells with already reduced OSBP levels did not significantly rescue the OSBP 
levels (Figure 10). These results indicates that the longterm repression of OSBP was not 
 
Figure 9: Chromatogram of SCMS quantificaiton of OSW-1 (m/z 895.44)  at 0 h 
and 24 h post washout of a 100 nM treatment for 1 h using an internal standard of 
deuterated OSW-1 (m/z 898.46). Phosphatidylcholine (m/z 782.56) is used as a 





due to the calpain protease. The long-term repression of OSBP was also shown to be 
independent of OSBP transcription inhibition, proteasome activity, or autophagy.90 
 
 
2.5.4 OSW-1 and THEV2 bind OSBP and ORP4 
In addition to OSW-1, the antiviral compounds ITZ, TTP, and THEV2 were 
reported to function through targeting OSBP.62–64 To compare these other compounds to 
OSW-1, binding of the ITZ, TTP, and THEV2 to OSBP and ORP4 using the well-
established 25-OHC competitive binding assay was performed.60,106 We demonstrated 
 
Figure 10: Western blot analysis of OSBP levels in HEK-293 cells of A) 24 h co-
incubation of OSW-1 1 nM and calpain inhibitor ALLN 10 µM, and B) following 6 
h 1 nM treatment of OSW-1, washout, recovery for 24 h and treatment with calpain 




               
               
               



























































Figure 11: Competitive binding of OSW-1, THEV, TTP and ITZ to OSBP and 
ORP4 using the 25-OHC competitive binding assay. Example of results from one 
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that the OSW-1 molecule and THEV2 were the only two compounds to displace 25-OHC 
binding to OSBP and ORP4; TTP and ITZ shown no competitive binding to 25-OHC 
(Figure 11). The OSW-1 OSBP Ki = 16 ± 4 nM and ORP4  Ki = 22 ± 15 nM.  THEV2 
OSBP Ki = 71 ± 6 nM and ORP4 Ki = 98 ± 14 nM.  Furthermore, OSW-1 was the only 
compound capable of reducing OSBP levels in cells  (data not shown).45 
 THEV2 binds to OSBP and ORP4 with an affinity similar to OSW-1, but unlike, 
OSW-1, THEV2 shows no cytotoxicity at concentrations up to 10 µM. (data not shown).45 
Co-incubation of 10 mM of THEV2 with OSW-1 in HEK-293 cells induces a slight, non-
significant decrease in OSW-1 cytotoxicity with OSW- (Figure 12). Co-incubation of 
OSW-1 with TTP or ITZ had no effect on the OSW-1 cytotoxicity curve (Figure 12). 
The apparent shift of the OSW-1 growth curve upon co-incubation with THEV2 supports 
the compounds bind in overlapping binding sites in OSBP and ORP4, as shown in Figure 
11.  




















Figure 12: Growth inhibition analysis of co-administration of OSW-1 with either 10 






2.5.5 OSW-1 selectively exhibits prophylactic activity 
To evaluate the extent of antiviral activity of the OSBP-targeting compounds, 
HeLa cells infected with two Enterovirus pathogenic viruses (i.e., echovirus2 and 
coxsackievirus 9a), and were treated with each of the compounds. Cells were treated with 
1 nM OSW-1 and 10 µM THEV2, TTP, and ITZ. All compounds had antiviral activity, 
although OSW-1, THEV2, and ITZ were all more potent at inhibiting viral replication 
 
Figure 13: A. Antiviral activity of TTP (10 µM), ITZ (10 µM), THEV2 (10 µM), or 
OSW-1 (10 nM). Cells were inoculated with virus at an MOI of 1 and treated with 
compound for 10 h. B. Profilactic activity of each compound. Compounds were 
administered for 6 h, washed out, 24 h recovery, then infected with virus at MOI of 





than TTP in both virus models (Figure 13). To evaluate the prophylactic ability of each 
of the compounds, cells were pretreated with each compound for 6 hours. Then, the 
compound-containing media was removed, the cells washed three times with media, and 
incubated for 24 h in drug-free media. Then, the cells were infected with virus for 10 
hours. (Figure 13). Viral count was performed from the supernatant through TCID-50 
titration. OSW-1 was the only compound to exhibit prophylactic activity against both of 

















These results demonstrate that a short, transient, low dose treatment of the OSW-
1 compound is sufficient to induce the selective degradation (>90%) and repression of 
the OSBP protein for multiple days after the compound treatment has stopped in multiple 
immortalized cell lines (Figure 5). The 72 hour repression of OSBP following removal 
of the compound demonstrates a stable biological effect transferable to multiple 
generations of cells. The OSW-1 induced repression of OSBP proceeds through an 
unidentified cellular mechanism. The long term repression of the OSBP did not correlate 
to any signs of toxicity or morphological changes in cells, which might be expected if 
OSBP is an essential protein responsible for transferring lipids between organelle 
membranes (data not shown).107  Although the initial degradation of the OSBP protein is 
coordinated through the proteasome, the multi-day repression of the protein is 
independent of transcription repression, proteasome activity, the OSW-1 compound, 
autophagy, or calpain activity (Figure 10).107  Furthermore, because OSBP repressed 
cells do not exhibit any signs of cytotoxicity, growth arrest, or morphology changes, it 
can be concluded that this repression is specific to the OSBP protein and independent of 
global protein repression. Furthermore, confirming this, a global iTRAQ proteome 
analysis did not detect any systematic global protein changes.107  
 This long-term repression of OSBP is also specific to OSW-1 and not any other 
known putative OSBP targeting compounds, ITZ, TTP, or THEV2 (data not shown).108 
Although all four compounds exhibited antiviral activity, only OSW-1 and THEV-2 
complete for binding with 25-OHC (Figure 11, Figure 13). These results suggest ITZ 
and TPP bind OSBP in another pocket other than the oxysterol binding site.  Furthermore, 
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OSW-1 was the only compound to degrade OSBP and exhibit prophylactic activity 




 These results demonstrate that targeting the host protein OSBP with a low dose, 
transient treatment of the OSW-1 compound causes a non-toxic degradation and long-
term repression of the protein, which correlates with inhibition of Enterovirus replication. 
This unique, unidentified regulator mechanism of OSBP repression has obvious 
therapeutic effects and demands to be continually explored for designing a new class of 














Chapter 3: OSW-1 Compound Anti-cancer Development in Ovarian 
Cancer Targeting ORP4L Protein 
Abstract 
Oxysterol-binding protein (OSBP)-related protein 4 (ORP4) is a cancer-specific driver of 
cellular proliferation and a regulator of cellular metabolism. The natural product OSW-1 
targets ORP4 and its closely related paralog OSBP producing potent antiproliferative 
properties through an incompletely understood mechanism.  Although reported to have 
limited to no expression in normal tissue, ORP4 is putatively expressed in the majority 
of cancers, with specifically high expression in ovarian cancer. We demonstrate that 
ORP4 is strongly expressed in all ovarian cancer cell lines tested, including in three-
dimensional spheroid tumor-models. The nanomolar antiproliferative activity of the 
OSW-1 compound was correlated to ORP4 expression levels in the different ovarian 
cancer cell lines, both in monolayer and in spheroid models. The correlation of ORP4 
levels and OSW-1 potency suggests a precision targeting of the cancer-specific ORP4 
protein. Importantly the OSW-1 compound had comparable superior cytotoxicity in the 
ovarian cancer three-dimensional spheroids models compared to cisplatin and paclitaxel. 
OSW-1 compound treatment induces the degradation of ORP4, and the cytotoxicity 
correlated to the amount of ORP4 degradation, further supporting the identification of 
ORP4 as a potential precision cancer target in ovarian cancer. Further, the absence of 
extracellular lipids dramatically potentiated the cytotoxic effects of OSW-1 in monolayer 
cells, and this increase in OSW-1 potency was rescued by addition of extracellular 
cholesterol. These results suggest that ORP4 is a potentially druggable precision cancer 
target for ovarian cancer, and that the increased potency of the OSW-1 compound in the 
absence of lipids presents an opportunity for the compound to possibly selectively target 
nutrient/lipid deprived tumors in vivo. 
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3.1.1 Ovarian Cancer Background 
Ovarian cancer is the deadliest gynecological malignancy, with a 50% five-year 
survival rate causing over 14,000 deaths per year in the United States.109 The high 
morbidity and mortality of ovarian cancer is due to diagnosis commonly occurring after 
the metastatic spread of the cancer (Stage III or IV), at which point the treatment options 
are often limited and inefficient.110 The major type of epithelial ovarian cancer (EOC) is 
high-grade serous carcinoma (HGSC).111 Standard of care treatment of metastatic HGSC 
is a combination chemotherapy of a platinum-based drug (e.g., cisplatin or carboplatin) 
and an anti-mitotic agent (e.g., paclitaxel).112 HGSC malignancies are complicated due to 
an atypical route of metastasis. Unlike most epithelial cancers, HGSC disseminates 
through a transcoelomic route rather than a hematogenous or lymphatic route.111 The 
transcoelomic HGSC metastasis results in the dissemination of the cancer cells to vital 
organs throughout the abdomen cavity, which affects the gastrointestinal and 
genitourinary systems. This cancer pathophysiology also leads to ascites formation, 
increasing patient morbidity rates.111,113 Transcoelomic metastasis requires the HGSC 
cells to avoid anoiks (i.e., cell detachment programmed cell death) through formation of 
tumor spheroids, which provides the required cell-to-cell adhesion for the cancer 
cells.113,114 HGSC spheroid formation depresses the efficacy of the standard of care 
chemotherapy and promotes drug HGSC resistance.113 Also, the three dimensional HGSC 
spheroid structure is deficient in nutrient distribution, producing concentric gradients, 
resulting in an inner necrotic core surrounded by a layer of viable quiescent cells with an 
outer proliferating layer of cells.115,116 The clinical relevance of HGSC spheroids, 
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especially in the therapeutic treatment, has led to the development of three-dimensional 
(3D) cell culturing methods in the study of ovarian cancer. Ovarian cancer cell lines 3D 
spheroids models created in the research labs mimic the in vivo HGSC spheroid, including 
the cell-extracellular matrix (ECM) composition, requirement for cell-cell interactions, 
and transcriptome alteration, all of which cannot be achieved by traditional 2D culture117–
121. As a useful proxy of the clinical HGSC, 3D spheroid cell culture models, including 
ovarian cancer, has been used to test and identify new anticancer agents.122–124  
 
3.1.2 ORP4 Biology 
The natural product compound OSW-1 (Figure 1) is an exceptionally potent 
cytotoxic agent against a wide range of in vitro cancer cell lines (NCI 60 Avg. GI50 = 0.78 
nM).59 OSW-1 induces its cellular effects through binding to oxysterol-binding protein 
(OSBP) and OSBP-Related Protein 4 (ORP4)60,125. OSBP and ORP4 are cytoplasmic, 
non-enzymatic proteins belonging to a 12-member family of lipid transport and lipid 
regulatory proteins.126–129 OSBP is reported to be required for ER-Golgi lipid transport 
and for the replication of several classes of RNA pathogenic viruses.48,64 OSBP has no 
known role in cellular viability, cellular proliferation, or cancer biology.46–48,90 In 
contrast, ORP4 is an identified precision cancer target and driver of cancer cell 
proliferation. ORP4L is selectively expressed in patient-isolated T-cell acute 
lymphoblastic leukemia (T-ALL) cells and drives the leukemia proliferation, including 
in leukemia stem cells.51,53 ORP4 is reported to promote mitochondrial respiration in  
immortalized immune cells by regulating calcium release from the endoplasmic reticulum 
through mediating a G-protein activation of PLC3β.51 Knockdown of ORP4 in cancer cell 
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lines results in increased apoptosis, autophagy, and mitochondrial dysfunction, which 
phenocopies OSW-1 treatment.51,53–57 Unlike the ubiquitous expression of OSBP, ORP4 
is reported to have limited selective expression in only parts of the brain, retina, and testes 
(Figure 14).49 ORP4-/- mice develop normally, aside from male sterility, signifying the 
limited role of ORP4 in non-transformed tissue.130  
Herein, we describe the ORP4 expression in a series of ovarian cancer cell lines, 
including ovarian cancer cells cultured as three-dimensional spheroids. We demonstrate 
that the ORP4-targeting compound OSW-1 shows potent cytotoxicity relative to SOC 
chemotherapy agents cisplatin and paclitaxel in both monolayer (2D) and spheroid (3D) 
ovarian cell line models. To produce these results, we provide extensive characterization 
of spheroid development in multiple ovarian cancer cell lines, producing an ideal in vitro 
model for investigating small-molecule pharmacology on in vivo tumors and circulating 
spheroids. The toxicity of the OSW-1 compound is suggested to have a unique biological 
mechanism of ORP4L protein degradation due to OSW-1 compound binding resulting in 
cell death independent of OSBP protein degradation. Lastly, the absence of extracellular 
lipids, modeling a nutrient deprived tumor, significantly potentiated the cells specific to 
the OSW-1compound with the addition of extracellular cholesterol attenuating this effect, 








3.2.1 Cell Culture 
OVCAR-3 (ATTC # HTB-161), OVCAR-8 (NCI-Vial Designation 0507715), 
and OVSAHO (JCRB-1046) were cultured in RPMI Medium (Thermo 22400105) with 
the addition of 10% Hyclone (Fisher Sci SH3006603) and 1% penicillin-streptomycin 
(Thermo 15140122). SKOV-3 (HTB-77) were cultured in McCoy 5A media (Thermo 
16600108) supplemented with 10% Hyclone and 1% penicillin-streptomycin. All 
mammalian cell lines were cultured at 37 °C in 5% CO2 in either Nunclon Delta 10 cm2 
dishes (VWR 10171744), T25 flask (CellStar 690160) or T75 flask (TPP 90076). 
 
3.2.2 2D Viability Assay 
Cells were seeded out in a 96-well plate in 75 µl of media at a cell number of 5.0e3 
per well. Compounds were serial diluted at 4X concentration in medium. 25 µl of 
compound containing media was added to 75 µl of cells, resulting in a 1X dilution of 
drug. Following a 72 h incubation, CellTiter-Blue was added for 20 h, and fluorescence 
was measured (544nm excitation; 590nm emission) using a plate reader. Growth relative 
to untreated cells were calculated expressed as IC50 values on Graphpad Prism software 
utilizing the four-parameter-dose-response curve.  
 
3.2.3 Spheroid Development 
Spheroid formation was induced by the ultra-low attachment technique. Briefly, 
round bottom 96-well plates (CELLTREAT 229590) were treated with anti-adherence 
rinsing solution (STEMCELL 07010) by centrifuging the plates at 1300 g for 5 min. The 
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solution was aspirated, and wells were washed with basal medium. OVCAR-8 or SKOV-
3 cells were seeded in 200 µl of media at the desired cell number and plates were 
centrifuged at 100 g for 3 min. For OVCAR-8 spheroids 100 µl of medium is removed 
and 100 µl of fresh medium was added every 24 h. For SKOV-3 spheroids, 100 µl of 
medium was removed on day 4 and 100 ul of fresh medium was added until day 7. 
Spheroid formation was observed for 7 days by monitoring the formation every 24 h with 
bright field imaging. Spheroids were characterized for their surface area, circularity, and 
solidity by using ImageJ.  
 
3.2.4 3D Viability Assay 
Spheroid viability was measured by using CellTiter-Glo3D. The solution was 
thawed overnight prior to experiments. 96-well plates and CellTiter-Glo3D solution were 
equilibrated to room temperature prior to use. Briefly, 100 l of CellTiter-Glo3D solution 
was added on top of 100 l spheroid solution. Contents were vigorously mixed to induce 
lysis of the spheroid and efficient extraction of ATP. Plates were incubated at room 
temperature for 25 minutes for stabilization of luminescent signal. After the incubation 
period luminescence was recorded by using an integration time of 1 second per well, 
accordingly with the manufacturer’s instructions. Toxicity was calculated relative to an 
untreated control group. No spheroids were formed on the outside wells of the 96 well 
plate to avoid edge effect.  
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3.2.5 Cell Lysis 
Adherent cells were lysed by aspiration of media, wash with 1X PBS, addition of 
TrypLETM Express (Gibco 12605- 010), and neutralized through the addition of media. 
Cells were spun at at 14,000 RCF for 0.45 min at 4°C. Supernatant was aspirated, cell 
pellet washed with 1X PBS, and resuspended in 50 µL of AC lysis buffer (150 mM NaCl, 
1.5 mM MgCl2, 5% glycerol, 0.8% NP40, 1mM DTT, 50 mM HEPES, 25 mM NaF, 1 
mM Na3PO4) with 3X HALT/EDTA protease inhibitor (Thermo 78438) and 0.2 mM 
phenylmethanesulfonylfluoride (Goldbio). Cells were freeze/ thawed (X3) with LN2 and 




SDS-PAGE gels (8.5%) were loaded with 25 µg of protein, transferred to 
nitrocellulose membrane ((Bio-Rad 1620115) with a constant voltage of 100V for 1 h at 
4C. The membrane was blocked in 5% milk for 0.5 h. Following washing with TBST 
(X3), the membrane was incubated with 1:500 ORP4 antibody (Santa Cruz sc-365922) 
or 1:1000 OSBP antibody (Santa Cruz sc-365771) overnight at 4C. Following washing, 
the membrane was incubated with 1:3000 Secondary antibody (Santa Cruz sc-2060) for 
1 h at RT. Following washing, the membrane was developed with ClarityTM Western 
ECL substrate (Bio-Rad 1705061) and imaged on the Bio-Rad ChemiDocTM Touch 
Imaging System. The membrane was incubated with 1:1000 β-actin HRP (Santa Cruz sc-
47778 HRP) after washing and developed as previously described.  
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3.2.7 Trypan Blue Viability 
Following compound treatment, media was transferred to a new 15 mL falcon 
tube. Adherent cells were washed with 1X PBS, addition of 2.5 mL TrypLETM Express, 
and neutralized by addition of used media. Cell count and viability was performed using 
Trypan Blue (Thermo 15250061) with a TC20™ automated cell counter (BioRad).  
 
3.2.8 Delipidated FBS Media 
FBS was delipidated through a Brown and Goldstein modification of the method 
developed by Cham and Knowles. Briefly, 50 mL of FBS was added to a mixture of n-
butanol and di-isopropyl ether in a 40:60 (v:v) ratio. The solution was incubated for 20 
min at RT followed by a 20 min incubation on ice. The solution was centrifuged at 2000 
rpm for 2 min. The lower aqueous fraction was isolated and re-extracted with 50 mL of 
di-isopropyl ether followed by centrifugation. The resulting aqueous phase was 
evaporated to 20 mL under Nitrogen gas and dialyzed to PBS O/N and filter sterilized. 
The 20 mL of delipidated FBS was added to 500 mL of media supplemented with 1% 
penicillin-streptomycin. 
 
3.2.9 Statistical Analysis 
All results are displayed as mean ± SD. A minimum of n = 3 was performed for 
each experiment. Statistical analysis was performed in GraphPad Prism 8.3.) using 2-way 




3.3.1 ORP4 is ubiquitously expressed in ovarian cancerous cells in vitro. 
Analysis of the publicly available human RNA expression datasets shows that 
ORP4 has minimal expression in normal ovarian tissue but is highly expressed in ovarian 
cancers (Figure 14). We evaluated the expression of ORP4 relative to OSBP in four 
HGSC immortalized cell lines: SKOV-3, OVCAR-8, OVCAR-3 and OVSAHO. SKOV-
3, OVCAR-3, and to a lesser extent, OVCAR-8, are extensively used ovarian cell line 
model systems reported to be genetically dissimilar to patient derived ovarian cancer 
samples. 131 Conversely, OVSAHO is reported to more closely recapitulate ovarian 
cancer patient samples, and therefore OVSAHO would be a  more informative pre-
clinical model system for studying ovarian cancer than the other established cell lines. 131 
Although all four ovarian cancer cell lines expressed ORP4, there were significant 
relative differences in expression of ORP4 in the individual cell lines. The OVCAR-8 and 
OVSAHO cell lines showed approximately two-fold more ORP4 expression than SKOV-
3 and OVCAR-3 (Figure 14). In contrast, the level of relative OSBP expression did not 
vary between the four cell lines (Figure 14). 
 
3.3.2 OSW-1 is a potent inhibitor of cancer cell proliferation. 
To assess the efficacy of the OSW-1 compound (Figure 14), it was compared to 
the clinically used ovarian anti-cancer compounds, paclitaxel and cisplatin, against our 
ovarian cancer cell line panel in a monolayer (2D) viability assay (Figure 15). 
Compounds were administered for 72 h at the provided concentrations and toxicity was 
quantified relative to vehicle control using cell titer blue. The OSW-1 compound 
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exhibited potent, low nanomolar toxicity against three of the four ovarian cancer cell lines 
(SKOV-3, OVCAR-3, and OVSAHO), showing a higher potency than both clinical 
drugs, paclitaxel and cisplatin (Figure 15). Unexpectedly, the OSW-1 compound was 
 
Figure 14: The antineoplastic compound, OSW-1, protein binding partner, ORP4, 
is a selectively expressed cancer protein. A.) The OSW-1 compound. B.) RNA 
expression in human tissues from the FANTOM5 dataset. C.) Patient percentage 
that have at least medium expression of ORP4 in cancer tissue. Data collected from 
the Human Protein Atlas. Patient samples ≥ 9. D.) Western blot of OSBP and ORP4 
in all four ovarian cell lines. E.) Quantification of OSBP and ORP4 in ovarian 





ineffective at producing toxicity in OVCAR-8 cells up to 1 µM yet remained sensitive to 
paclitaxel and cisplatin treatment (Figure 14). It should be noted that the OSW-1 
compound did induce morphological changes, exhibiting less cell-cell interactions, to the 
OVCAR-8 cell line starting at 1.0 nM (Figure 18), however, it did not correlate with 
toxicity (Figure 15, Figure 18). Furthermore, the OVSAHO cell line showed resistance 
to paclitaxel (GI50 N/Q) but was still sensitive to OSW-1 (GI50 1.8 nM). Together, these 
results suggest the OSW-1 is a potent, cytotoxic agent of ovarian cancer cells in vitro. 
 
Figure 15: OSW-1 is a cytotoxic agent to monolayer ovarian cancer cells. A-D) 
Growth inhibition curves of Paclitaxel, OSW-1, and Cisplatin in four ovarian cell 








3.3.3 Ovarian cancer cells produce in vitro spheroids. 
3D tumor spheroids provide a better representation of in vivo tumors compared to 
conventional 2D culture.124 Spheroid formation occurs through aggregation of cells and 
has been developed by using different techniques; hanging drops132,133, ultra-low 
attachment134, spinner flasks135, and agarose coating136. Even though each technique 
results in spheroid formation, the specific spheroid generation technique has been shown 
to influence drug toxicity137. OVCAR-8 and SKOV-3 spheroids were initiated with 
different cell numbers using the ultra-low attachment method and their growth for 7 days 
was monitored and their surface area was calculated by using ImageJ. OVSAHO and 
OVCAR-3 cells were unable to form compact spheroids using this method. Initial cell 
numbers for spheroid formation was selected to obtain similar sizes of spheroids at day 
7. For both cell lines 5000, 10000, and 20000 cells were seeded on round bottom 96-well 
plates and monitored for their spheroid formation over 7 days. A total of 8 spheroids for 
each cell density seeding were analyzed for their surface area. OVCAR-8 spheroids 
initiated with 5,000 cells and SKOV-3 spheroids initiated with 20,000 cells resulted in 
similar sizes on day 7. Compared to SKOV-3 cells, OVCAR-8 cells aggregated within 
the first 24 h and formed spheroids even within 48 h. Additionally presence of FBS in the 
medium resulted in disruption of the spheroid formation around day 4 for SKOV-3 cells 
Previously, spheroid formation has been described in serum-free conditions. Therefore, 
SKOV-3 spheroids were initiated without the presence of FBS and within 4 days 
spheroids had clear boundaries (Figure 16). 
49 
After obtaining the cell numbers resulting in similar spheroids size 
characterization of spheroids was carried out with these cell confluences. For 7 days, 
spheroids were characterized for their projected surface area (Figure 16). Circularity and 
solidity measurements were carried out on day 7 (Figure 16). OVCAR-8 spheroids 
increase in size over the course of 7 days and had clear boundaries around day 2, while 
SKOV-3 cells formed spheroid boundaries around day 4 and did not increase in size due 
to lack of FBS in the media (Figure 16). Both spheroids had circularity more than 0.9 and 
had solidity more than 0.95 indicating the formation of dense and circular spheroids.138  
 
Figure 16: OVCAR-8 and SKOV-3 ovarian cancer cells form spheroids in vitro. A.) 
Schematic of spheroid formation in ovarian cell lines. B.) OVCAR-8 and SKOV-3 
spheroid development over 7 days. White bar represents 250 µM. C.) Quantification 






3.3.4 OSW-1 is a potent cytotoxic agent to ovarian spheroids in vitro 
In order to test the OSW-1 compound in a more clinically relevant model, OSW-
1, paclitaxel, and cisplatin were evaluated for their toxicity on a spheroidal (3D) assay 
generated from OVCAR-8 and SKOV-3 cells. (Figure 17). Toxicity of the compounds 
were analyzed by using CellTiter Glo 3D ATP detection mechanism instead of standard 
colorimetric methods which have been shown not applicable in 3D systems139,140.  
 
Figure 17: The OSW-1 compound is potent, cytotoxic agent to in vitro generated 
ovarian cancer spheroids. A.) OVCAR-8 spheroid images at 72 h post treatment. B.) 
SKOV-3 spheroid images at 72 h post treatment. C.) OVCAR-8 spheroid toxicity 
quantification relative to control using Cell-Titer Glo. (n = 3). D.) SKOV-3 spheroid 





Following 7 days of growth, spheroids were treated with the provided concentration of 
compound and analyzed for viability following 72 h. OVCAR-8 spheroids were not as 
responsive to paclitaxel treatment (50% cell death at 100 nM) compared to the monolayer 
treatment (GI50 58 nM) but exhibited similar sensitivity toward cisplatin treatment (50% 
cell death at 10 μM in spheroids and GI50 22 μM in monolayer) (Figure 17). Interestingly, 
OSW-1 treatment resulted in a dose dependent loss of viability in OVCAR-8 spheroids 
with 50% cell death at 100 nM, in contrast to monolayer cells showing resistance up to 1 
 
Figure 18: OSW-1 cellular morphology and viability. A) 40X magnification of 
OVCAR-8 and SKOV-3 monolayer (2D) following the provided treatments of 



















































µM. SKOV-3 spheroids were resistant to paclitaxel treatment exhibiting less than 25% 
cell death up to 10 μM and showed an increased resistance toward cisplatin treatment 
with less than 50% cell death at 10 μM. (Figure 17). Similar to OVCAR-8 spheroids, 
 
Figure 19: Ovarian cancer viability is correlated with ORP4L degradation and 
independent of OSBP expression upon OSW-1 treatment. A.) OSBP and ORP4L 
protein expression in 2D and 3D following the provided treatments of OSW-1 for 48 





OSW-1 inhibited SKOV-3 spheroid viability in a dose-dependent manner with 50% cell 
death at 1 nM, comparable to the 2D model (GI50 4.0 nM) (Figure 17). Furthermore, 
paclitaxel and cisplatin treated spheroids maintained their compact spheroid structure for 
the initial 48 h even at 1 mM concentration, however OSW-1 treatment clearly indicated 
disruption of spheroid boundaries around 10 nM which is 100-times lower than paclitaxel 
and cisplatin. These results indicate that OSW-1 is a potent cytotoxic agent of in vitro 
generated ovarian cancer spheroids, showing toxicity even when the SOC paclitaxel and 
cisplatin are incapable of inducing cell death.  
 
3.3.5 OSW-1 toxicity is independent of OSBP degradation and correlates with ORP4L 
levels.  
To address the mechanism of OSW-1 toxicity, both the OSBP and ORP4 levels 
were analyzed upon different concentration treatments of OSW-1 in both SKOV-3 and 
OVCAR-8 2D and 3D cultures following 48 h of treatment. Previous studies have 
demonstrated that low dose OSW-1 treatment (1 nM) results in selective degradation of 
the OSBP protein in a monolayer cell model60,90. We also observed >60% OSBP 
degradation with as little as 0.1 nM OSW-1 for 48 h in both a 2D and 3D model with no 
signs of toxicity (Figure 18). An increasing amount of OSW-1 compound (i.e, 1.0 nM 
and 1.0 µM) resulted in a non-significant difference in OSBP levels compared to the 0.1 
nM treatment (p value > 0.05) (Figure 18). ORP4L protein levels, however, correlated 
closely with the viability of the cells in a 2D model, resulting in an OSW-1 concentration 
dependent degradation of the protein (Figure 18). The degradation of ORP4L was also 
evident in a 3D cell model correlating to viability in an OSW-1 dependent manner with 
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> 80% protein degradation at 1 μM in both SKOV-3 and OVCAR-8 spheroids (Figure 
18, Figure 17). The higher levels of degradation of the ORP4 protein upon 1.0 µM 
treatment in OVCAR-8 spheroids (87%) compared to the monolayer (63%), could 
suggest a rationale into its increased toxicity to the OSW-1 compound in a 3D model. 
Furthermore, the lower, but not significant (p value > 0.0.5) levels of the OSBP and 
ORP4L protein in OVCAR-8 spheroids compared to monolayer could also influence the 
increase toxicity to OSW-1. Together, these results demonstrate an OSBP independent 
cytotoxicity mechanism of action, suggesting that the degradation of the ORP4L protein 
due to OSW-1 compound binding correlates with cellular viability in vitro.  
 
3.3.6 OSW-1 toxicity is regulated based on extracellular lipids.  
In vivo tumors are increasingly characterized by having hypoxic conditions and 
nutrient gradients in accordance with their distance from the nearest vasculature, this 
includes essential amino acids and sugars, but also lipids141. This absence of lipids 
demands a dependence on endogenous lipid biosynthesis. To further explore the 
discrepancy in OSW-1 toxicity between the 3D and 2D cell models of OVCAR-8, OSW-
1 toxicity was monitored in both the presence and absence of extracellular lipids in a 2D 
model. OVCAR-8 and SKOV-3 cells grown in this delipidated condition exhibited little 
to no changes in growth and phenotype but exhibited a significant change in toxicity to 
the OSW-1 compound (Figure 19). OVCAR-8 cells exhibited a significant -200,000 fold 
change in sensitivity to the compound in delipidated media (GI50 0.06 nM) (Figure 19). 
This effect was also seen in SKOV-3 with a -180 fold change in sensitivity in delipid 
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media (GI50 0.02 nM) (Figure 19). Intriguingly, the addition of exogenous cholesterol to 
the delipid media attenuated the potency of the OSW-1 compound (Figure 19). 25-OHC, 
an endogenous ligand to the OSBP and ORP4 protein and also an inhibitor of β-Hydroxy 
β-methylglutarly-CoA (HMG-CoA), an essential enzyme for endogenous cholesterol 
synthesis, also showed an increase in toxicity in the absence of lipids as expected, and the 
addition of cholesterol completely rescued the cells with no detectable toxicity up to 10 
μM (Figure 19). Importantly, the change in toxicity in the delipid media was specific only 
to the OSW-1 compound and not due to a global cellular stress response (e.g. paclitaxel 
treatment). Together, these results demonstrate a unique mechanism of action specific to 
 
Figure 20: OSW-1 toxicity is potentiated in the absence of extracellular cholesterol.  
A) Growth inhibition curves of 2D OVCAR-8 cells and B) SKOV-3 2D cells with 
OSW-1, Paclitaxel, or 25-hydroxycholesterol incubated in either normal media 
(RPMI with 10% FBS), Delipid media (RPMI with 10% Delipid FBS), or 
cholesterol media (RPMI with 10% Delipid FBS and 20 µg/mL cholesterol). C) Fold 





the OSW-1 compound in the absence of exogenous lipids, potentially further explaining 






















We’ve identified the OSW-1 compound as a potent inhibitor of ovarian cancer 
growth in both a monolayer (2D) and spheroid (3D) cell model (Figure 15, Figure 17). 
The OSW-1 compound was able to induce cellular toxicity to ovarian cancer spheroids 
in the nano-molar range, whereas the clinically used therapeutics, cisplatin and paclitaxel 
were unable to induce a significant degree of toxicity under 10 µM. The toxicity of the 
OSW-1 compound was correlated with the degradation of the ORP4L protein and was 
independent of OSBP degradation (Figure 19). Intriguingly, the OSW-1 compound was 
significantly more potent in the absence of extracellular lipids in a 2D model and the 
presence of exogenous cholesterol rescued this effect (Figure 20).  
The OVCAR-8 cell line is the first cell line, to the best of our knowledge, to show 
resistance to the OSW-1 compound (Figure 15). The cell line does exhibit a significantly 
higher amount of the ORP4L protein, the proposed cytotoxic target of the OSW-1 
compound, which could lead towards its resistance (Figure 14). However, the OVSAHO 
cell line also has a large amount of the ORP4L protein relative to SKOV-3, but remains 
sensitive to the compound, suggesting that OVCAR-8’s resistance is not entirely due to 
elevated ORP4L levels. High dose OSW-1 treatment (1 µM) for 48 h in 2D OVCAR-8 
cells did not induce as much ORP4L degradation as in 3D (Figure 19), suggesting; 1) 
The ORP4L protein is essential for the viability of the cells; 2) the OSW-1 compound is 
able to cause the degradation of the protein, and; 3) this degradation could be regulated 
differently between 2D and 3D cultures, but could also be due to the difference, albeit not 
significant, OSBP and ORP4L protein levels between 2D and 3D. It should also be noted 
that 0.1 nM treatment of the compound was able to induce OSBP degradation in both 2D 
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and 3D cultures in each cell line tested, suggesting that the OSW-1 compound is able to 
penetrate into the cells, and the resistance of the OVCAR-8 cells is not due to compound 
entry.  
The significantly lower pico-molar GI50 values of the OSW-1 compound in 
delipidated media compared to normal 10% FBS supplemented media (Figure 20) could 
be due to targeting of the OSBP protein, the strongest known binding protein to the 
compound. This would correlate with the degradation of the OSBP protein seen in both 
2D and 3D culture as low as 100 pM treatment of the compound (Figure 19). 
Furthermore, the addition of cholesterol to the media rescuing this toxicity also suggests 
OSBP as the molecular target, since OSBP is known to traffic newly synthesized 
cholesterol from the Endoplasmic Reticulum to the Golgi Apparatus in addition to 
sensing cholesterol levels and controlling pERK activity, an essential pathway for cellular 
division43,142. The degradation of the OSBP protein is independent of toxicity in the 
presence of extracellular lipids, however (Figure 18). This suggests that the OSW-1 
compound would be a selective inhibitor for tumor growth by targeting both OSBP and 
ORP4. In this proposed model, 1. OSW-1 targets and degrades the cancer specific ORP4 
protein resulting in cellular death, and 2. OSW-1 targets and degrades the ubiquitous 
tissue expressed OSBP protein, resulting in cellular death only in cholesterol deprived 
conditions (e.g., tumor tissue).   
 
3.5 Conclusions 
Taken together, our data suggests that the OSW-1 compound is a more potent 
inhibitor of ovarian cancer compared to the clinically used compounds, cisplatin and 
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paclitaxel, in both monolayer and spheroids in vitro. This toxicity is suggested to be due 
to ORP4L degradation, but in the absence of extracellular cholesterol, the targeting and 
degradation of the OSBP protein may be toxic to the cells in a sub nano-molar 
concentration, producing an ideal therapeutic for ovarian cancer with the potential of 


















Chapter 4: Bio-Analytical Chemotherapeutic Drug Monitoring and 
Quantification of Gemcitabine in Single Cells  
Abstract 
The personalization of drug treatment requires capabilities to measure drug levels 
and efficacies in patients at the single-cell level since disease states are characterized by 
the biological activity of individual cells. Currently, there are no commonly used 
bioanalytical methods capable of real-time measurement of drug levels for the live single 
cells. The ability to quantify drug amount on the single-cell level is especially needed in 
the clinical treatment of cancer, because precisely measuring the amount of chemotherapy 
drug present in the individual cancer cells of a patient would allow for more adaptative 
and personalized administration of chemotherapy drugs. This would potentially lead to 
better clinical outcomes with fewer side effects. In this study, we report the quantification 
of the anti-cancer drug gemcitabine present in individual bladder cancer cells from both 
cell lines and patients undergoing standard chemotherapy. This bioanalytical innovation 
was achieved through development of a quantitative single cell mass spectrometry 
(qSCMS) sampling apparatus consisting of Single-probe mass spectrometry technology 
and an integrated cell manipulation platform (ICMP). The qSCMS analysis using the 
integrated Single-probe/ICMP system allows for the measurement of drug amount from 
individual cells. Particularly, the drug concentration can be obtained upon the 
measurement of cell size using the microscope of this integrated system. Our technique 
can potentially be developed into a rapid, real-time bioanalytical tool to more effectively 
and safely administer drug medications in patients.  
 
Allocation of Contribution 
This chapter is a submitted manuscript currently under review. I am co-first author 
on this manuscript. The data in this chapter is an accumulation of results from my 
collaborative work with Dr. Yang’s lab at the University of Oklahoma. My collaborative 
work includes the 2019 Analytical Chemistry publication.143 The research presented here 
was mainly conducted by myself and Dr. Standke, a former graduate student of Dr. 
Yang’s lab. Dr. Standke contributed the analytical chemistry expertise to the project, 
including probe fabrication, instrument maintenance, and operation of the mass 
spectrometer. I was responsible for all mammalian and clinical cell culturing and 
preparation and drug treatment. I also assisted in the operation of analytical data 
accumulation (assisted with the operation of the mass spectrometer/ main operator of the 
ICMP/ LCMS). Dr. Standke and I contributed equally with data analysis and drug 
quantification. I was the main contributor for the creation of all publication figures shown 
(Dr. Standke was responsible for Figure 21). Mr. Devon Colby assisted throughout the 




The current inability to quantify intracellular chemotherapy drug concentrations 
in cancer cells limits the personalization and overall effectiveness of drug administration 
in clinical cancer medicine. In this study, we report the development of a new quantitative 
single cell mass spectrometry (qSCMS) method capable of providing absolute drug 
amounts and concentrations (for spherical cells) in single cancer cells. Our qSCMS 
system is comprised of the Single-probe, a miniaturized sampling and ionization probe, 
combined with an integrated cell manipulation platform (ICMP). Using this qSCMS 
system, we conducted quantitative analysis of the intracellular drug gemcitabine present 
in individual bladder cancer cells, including those isolated from patients undergoing 
standard-of-care chemotherapy. The development of single cell pharmacology 
bioanalytical methods can potentially lead to more effective and safely administered drug 
medications in patients, especially in the treatment of cancer.  
New single cell analysis techniques have recently emerged, including DNA and 
RNA sequencing, microfluidics, imaging, flow cytometry, and mass spectrometry 
(MS).144–156 The pursuit of single cell mass spectrometry (SCMS) technology has led to 
the development of new and innovative  methodologies utilizing unique apparatuses, 
ionization technologies, and microscopy.157–167 Research into the treatment and study of 
cancer is a major potential application of SCMS methods. Understanding abnormal 
biology at the single cancer cell level is an increasing focus of cancer biology. Cancer 
stem cell theory and the clinical relevance of circulating tumor cells (CTC) are examples 
of the single cell focus of cancer research.168–170 
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SCMS also has the potential to improve the administration of drug compounds in 
clinical cancer medicine. The use of SCMS in drug development and in drug 
administration will be especially important in the emergence of effective precision 
medicine. Ideally precision medicines in the clinical treatment of cancer should combine 
new targeted treatments with the capability of assessing, in a time-relevant manner, the 
efficacy of drug treatments in individual patients.171 The current lack of meaningful, real-
time bioanalytical measurements in cancer patient drug administration limits the 
personalization and responsiveness of the treatment. Due to inter-individual 
pharmacokinetics/ pharmacodynamics (PK/PD), the amount of drug present in patient 
serum often does not report on the amount of drug present at tumor sites.172,173 The 
measurement of chemotherapy drug concentrations in biopsied tissue isolated from tumor 
sites might not represent the intracellular drug concentration in the tumor cells for 
multiple reasons. Tumor tissue samples are usually a complex, heterogenous mixture of 
cancer cells and non-cancer cells, and multi-drug resistant (MDR) cancer cells engage P-
glycoprotein pumps to extrude therapeutic drugs into the extracellular tumor space.16 Due 
to these limitations in bioanalysis in drug administration, most chemotherapy drug dosage 
is determined by a patient’s gross physical characteristics, such as body surface area, 
rather than any personalized or cancer-specific criteria.174 Further, the chemotherapy drug 
regimen is commonly administered using a non-adapting, fixed schedule with efficacy 
determined from an endpoint analysis, such as an imaging scan (e.g., PET scan), after 
weeks or months of drug chemotherapy drug administration175. Patients, therefore, are 
required to endure extensive, non-personalized chemotherapy dosing with its potential 
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associated adverse side effects before any determination if the treatment will have any 
efficacy.  
The development and application of SCMS bioanalytical methods for the 
detection, quantification, and biological activity of drug compounds would be a powerful 
tool to provide real-time feedback of therapeutically-relevant treatment efficacy.176 Our 
established Single-probe SCMS technology allows for the analysis of small molecules 
from individual cells, which are attached onto substrate (e.g., glass cover slip) surfaces, 
under ambient conditions.84,177 Using an isotopically-labeled deuterated irinotecan drug 
compound analog as an internal standard, we utilized the Single-probe system to 
successfully perform quantitative single cell mass spectrometry (qSCMS) in measuring 
the intracellular amounts of the anticancer drug irinotecan in single adherent cancer 
cells.178 To further extend the SCMS analytical methods to non-adherent suspended cells 
with minimal interferences from complex sampling matrices, we coupled the Single-
probe device with an integrated cell manipulation platform (ICMP) (Figure 21).179  The 
ICMP, consisting of an inverted microscope, two cell manipulation systems, a 
microinjector, and a glass cell-selection probe, is capable of distinguishing cell types, 
morphologies, and sizes as well as capturing individual cells for analysis. 179 
Here, we report the development and the application of the Single-probe/ICMP 
system to quantify the amount of standard-of-care cancer drug gemcitabine in single 
cancer cells. Using the Single-probe/ICMP system, we for the first time performed 
qSCMS measurement of the amount of an anticancer drug in bladder cancer cells isolated 
from patients undergoing intravenous chemotherapy. 
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4.2 Methods 
4.2.1 Sample Preparation  
Adherent Cell Line: For the adherent bladder cancer cell line model, T24, cells 
were plated (2x105) into each well of a 6-well plate containing a poly-D-lysine-coated 
glass microchip with chemically-etched microwells (25 µm x 55 µm) and McCoy’s 
Media 5a supplemented with 10% FBS and 1% penicillin-streptomycin. Approx. 36 h 
after initial seeding, the media in each well is replaced with Gemcitabine-containing 
media at the indicated concentrations and incubated at 37°C and 5% CO2 for the duration 
of the treatment time (1 h). Prior to analysis, each glass microchip is rinsed with FBS-
free media (5 mL) to avoid the detection of Gemcitabine from extracellular species. Cells 
were tested using the traditional Single-probe setup, modified for quantification 
Suspended Cell Line: The human chronic myeloid leukemia cell line, K562, were 
grown in T25 flasks at 37°C and 5% CO2 in RPMI media supplemented with 10% FBS 
and 1% penicillin-streptomycin. Prior to treatment (24 h), K562 cells (5x105) were seeded 
out in a T25 flask. The cells were spun at 1500 RPM for 5 min and treated with 
Gemcitabine at the indicated concentrations at a 4 mL volume in a 15 mL Falcon tube. 
After treatment, cells were pelleted at 1500 RPM for 5 min at 37°C and washed 3 times 
with PBS (10 mL). All tubes were resuspended in PBS (3 mL/tube) and were used for 
analysis in a 3 mL petri dish. K562 cells were analyzed using the integrated cell 
manipulation platform (ICMP) in conjunction with quantitative single cell mass 
spectrometry using the Single-probe mass spectrometry technique. 
Patient Samples: Two separate groups of bladder cancer patients’ urinary cells 
were analyzed in this study. One group (n=2) was not subjected to gemcitabine, while the 
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other (n=2) received 1000 mg/m2 infusion of gemcitabine. The urine was collected in a 
specimen jar for the analysis of the non-treated patients and collected 1 h after infusion 
for the treated patients. The urinary sample was processed and analyzed within 3 h after 
collecting. Each sample was processed as followed:  sample was spun at 1500 RPM for 
5 minutes at 37°C, followed by washing with pre-warmed PBS (20 mL) 3 times. The cells 
were resuspended in PBS (2 mL), and the cell solution was placed into a 3-mL petri dish 
for analysis using the ICMP. 
 
4.2.2 Single Probe Fabrication  
Dual-bore quartz tubing (OD: 500 µm; ID: 127 µm) was pulled into a sharp needle 
(OD: ~5 µm) using a micropipette laser puller. Fused silica capillary (OD: 110 µm, ID: 
40 µm) was placed into one bore as a solvent-providing capillary. The same diameter 
capillary was flame-pulled and placed into the other channel of the dual-bore quartz 
needle as a nano-ESI emitter. The probe was sealed using UV resin and secured on a glass 
slide with Epoxy glue for easy coupling to the flexible arm clamp of either the X, Y, Z-
translational stage (adherent cells) or TransferMan manipulation system (suspended 
cells). 
 
4.2.3 Glass Cell-Selection Probe Fabrication  
Single-bore glass tubing (ID: 0.3 mm, OD: 1.1 mm) was transformed into a glass 
cell-selection device using a vertical pipette puller. Briefly, the glass was heated to create 
a tapered tip (~15 µm in diameter) to encompass an individual cell. Once the probe was 
pulled apart, it was placed in a Microforge MF-9 and bent ~45° from its original position.  
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4.2.4 Integrated Cell Manipulation Platform  
The Single-probe setup has been modified to accommodate an Eppendorf cell 
manipulation system, which utilizes both a Single-probe and a cell-selection device that 
allows the analysis of samples from a complex matrix with minimal sample preparation. 
The system is composed of an Eppendorf TransferMan cell manipulation system, Nikon 
inverted microscope, a Tokai Hit ThermoPlate, and a glass cell-selection device. The cell-
selection device was held in place and controlled through an Eppendorf TransferMan cell 
manipulation system. The Single-Probe was controlled through a second TransferMan 
system and stabilized with a flexible arm clamp. This system was constructed on a 
motorized table for convenient coupling to the Thermo LTQ Orbitrap XL mass 
spectrometer.  
 
4.2.5 Single-Cell Mass Spectrometry Analysis  
The Single-probe’s nano-ESI emitter was aligned with the extended ion transfer 
tube’s inlet. The solvent-providing capillary of the Single-probe was programmed to 
deliver solvent (internal standard dissolved in acetonitrile with 0.1% formic acid) at a 
flow rate of ~100 nL/min. Analysis was performed using a Thermo LTQ Orbitrap XL 
mass spectrometer. Positive ionization mode was used with a voltage of ~4.5 kV applied 
to the conductive union during analysis. (The flow rate and ionization voltage were 
optimized for each experiment due to varying tip size, emitter length, and emitter distance 
from the mass spectrometer’s inlet). A resolution of 60,000 and 1 scan/100 ms maximum 
injection time were used. 
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Adherent Cell Line: The glass microchip was placed on an X, Y, Z-translational 
stage controlled through the LabView software package, which allows controlled 
movements in 0.1 µm increments. Cells are monitored using a top-view digital 
stereomicroscope. Once an individual cell is selected, the stage is lifted in the z-direction 
for insertion. Microscale extraction of cellular content occurs and is introduced to the 
mass spectrometer after ionization using the nano-ESI emitter. 
Suspended Cell Line: Cells are placed in the lid of an 18-mm petri dish placed on 
a ThermoPlate at 37°C to mimic the cellular environment. During analysis, cells are 
monitored using an inverted microscope. Once a cell is chosen, suction is gently applied 
to the glass cell-selection device by changing the mineral oil in the CellTram Vario 
microinjector to secure a cell, and the cell-selection device is lifted in the Z-direction until 
aligned with the Single-probe tip. Once a liquid junction is formed between the two 
probes, suction from the cell-selection device is released for cell transfer. The cell 
undergoes microscale lysis and extraction and is taken up through drag force and capillary 
action before being sprayed into the mass spectrometer for analysis. 
 
4.2.6 Liquid-Chromatography Mass Spectrometry Analysis  
K562 cells (5x105) were seeded out in T25 flasks. After 24 h, cells were spun at 
1500 RPM for 5 min and resuspended in 4 mL of RPMI media supplemented with 
Gemcitabine at the desired concentration. Following 1 h, cells were washed (X3) with 
PBS and resuspended to a total volume of 1 mL in PBS. Cells were counted using an 
automated cell counter (Bio-Rad TC20TM) and were lysed using 1 mL of cold acetonitrile 
spiked with 100 nM of isotopically-labeled gemcitabine for 10 min with brief vertexing. 
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Cell lysate was spun at 15,000 RCF for 15 min at 4 °C. Supernatant was transferred to a 
new tube and dried with a speed vacuum (Savant SPD11V, Thermo Scientific) at 70 °C 
for 1 h. Samples were resuspended in 150 µL 12: 88 Acetonitrile: water. Liquid 
chromatography was performed using a Waters nanoAQUITY BEH C-18 Column (100 
µm x 100 mm, 1.7 µm) at 30 °C, a flow rate of 0.4 µL/ min, and a voltage of 2 kV. 
Mobile phase A is acetonitrile with 0.1% formic acid, and mobile phase B is water. A 
15 min isocratic gradient was used with an A: B composition consisting of 12:88. 
Data acquisition was performed on a biological triplicate. (n=3). 
 
4.2.7 Isotopically-labeled Gemcitabine 
Stable-isotopically labeled gemcitabine was accessed through a short sequence of 
reactions following the synthetic route that scientists at Eli Lily published in 1991.180 The 
starting material 3,5-di-O-benzoate-2-deoxy-2,2-difluoro-D-ribofuranose 4.3 was 
purchased commercially as a mixture of both anomers. The hemiacetal mixture was then 
activated as glycosyl donor by conversion of the free hydroxyl group to a mesyl group in 
4.4 with good yield (82%). The glycosyl acceptor was prepared from commercially 
available 2-13C, 1,3-15N2 cytosine 4.5. Glycosyl acceptor 4.6 was prepared in situ from 
heating the mixture of cytosine 4.5 and hexamethyldisilane to reflux in presence of 
ammonium sulfate for 45 minutes. Utilizing the Vorbrueggen glycosylation method, the 
mesylated glycosyl donor 4.4 was reacted with silylated glycosyl acceptor 4.6 and 
trimethylsilyl trifluoromethanesulfonate as the activator in refluxing 1,2-dichloroethane 
for 48 hours. This reaction produced a mixture of protected isotopically labeled 
gemcitabine 4.7 (76% yield). The glycosylation reaction was presumed to proceed 
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through an SN1 pathway involving an oxonium ion intermediate, which resulted in a 
mixture of nucleoside anomers with the ratio of α : β being 1.3 : 1 as measured through 
1H NMR.  
Treating the mixture 4.7 with ammonia in anhydrous methanol effectively 
removed both benzoyl protecting groups. The anomeric mixture of deprotected 
nucleoside were successfully separated through semi-preparative reverse-phase HPLC to 
afford desired β-anomer (4.8 in 34% yield) and α-anomer (4.9 in 4.0% yield). The desired 
β-nucleoside 4.8 was then converted to the hydrochloride salt of gemcitabine 4.10 in the 
presence of equimolar HCl in isopropanol. The molecular weight of the stable-
isotopically labeled gemcitabine 4.10 was confirmed through high resolution mass 
spectrometry. 
 
4.2.8 Statistical Analysis   
All results are expressed as mean ± SD with a minimum of three biological 
replicates. All statistical tests were performed on Graph Pad Prism 8 using a Mann-
Whitney Test. The P values reported are as followed: *p ≤ 0.05, **p ≤ 0.01 ***p ≤ 0.001, 






4.3 Results  
4.3.1 The Integrated Cell Manipulation System 
To analyze intracellular metabolites from single, suspended cells, the previously 
established Single-probe was coupled to an integrated cell manipulation platform (ICMP) 
(Figure 21). The ICMP system coupled to the Thermo LTQ Orbitrap XL mass 
spectrometer allowed the capability of selecting one individual suspended cell and 
 
Figure 21: The Single-Probe/ICMP Setup. A) The integrated cell manipulation 
platform (ICMP) Single-Probe coupled with the Mass Spectrometer. B) Schematic 
Representation of the Single-Probe coupled with the ICMP. C) 40X magnification 





analyzing its intracellular metabolites by forming a liquid junction with the Single-probe, 
which serves as both a sampling and ionization device. The ICMP system consists of two 
Eppendorf TransferMan micromanipulation devices used to control both the cell selection 
device (small glass tubing with a small tip size) and the Single-probe. The Single-Probe 
nano-ESI was centrally aligned with the inlet of the extended ion transfer tube in order to 
interface with the mass spectrometer. The cell culture is placed on a Thermo Plate system 
set to 37°C on top of an inverted Nikon Eclipse TE300 inverted microscope to visualize 
the cells.  
To operate the Single-probe/ ICMP system, the suspended cell culture (3 mL) is 
placed in a lid of a 35x12-mm petri dish. Cells were evaluated using the inverted 
 
Figure 22: Lipid composition of a single, suspended K562 cell.  Zoomed-in mass 
spectrum from a single cell showing the representative species (m/z 750–850). 





microscope. Using the TransferMan, the cell-selection probe was moved to a cell of 
interest. A gentle suction was applied using the CellTram Vario filled with mineral oil. A 
digital stereomicroscope was used to visualize the transfer of the cell from this culture to 
the Single-Probe. Once a junction was formed, the cell undergoes a micro-lysis and the 
cellular contents were carried by a continuous flow of acetonitrile solvent in the Single-
 
Figure 23: Mass Spectrum of Taxol from a single K562 cell. Zoomed-in mass 
spectra showing molecular profiles (m/z 800─900) for (A) untreated and (B) treated 






Probe, ionized, and sprayed in the mass spectrometer. The mass spectrometry parameters 
consisted of a 60,000 mass resolution at m/z 400, mass range of 100-1000, ionization 
 
Figure 24: Mass spectra obtained from individual K562 cells. (A) Spectrum from a 
single cell treated with 1 µM gemcitabine for 1 hr. (B) Spectrum for a cell exposed 






voltage of +4.5kV, 1 microscan, 100ms max injection time, and automatic gain control.  
 
4.3.2 Adherent Cell Drug Identification  
The Single-probe/ICMP system was used to detect the accumulation of different 
drug compounds (Gemcitabine, Taxol, and OSW-1) inside single chronic myeloid 
leukemia cells (K562 cell line). Cells were subjected to either Gemcitabine (1µM) or 
Taxol (1 µM) for 1 h, or OSW-1 (1 µM/ 100 nM) for 2 h/ 4h, respectively.  The 
 
Figure 25: Metabolomic Anlalysis of individual K562 cells. PCA showing the 
overall difference of metabolomic compositions of single K562 cells in the control 





Phosphatidyl Choline (PC) lipid peaks PC(34:4), PC(36:4), and PC(38:5) at m/z 754.536, 
782.567, and 808.583, respectively, were highly ionizable and produced a reproducible 
signal depicting the analysis of cellular content in addition to numerous other PC 
identities (Figure 22). All PC peaks were subjected to MS/MS fragmentation to confirm 
the structures.  In addition to these peaks, among many other detectable molecular 
signatures, all three compounds were detected in individual K562 cells, but were not 
detected in the extracellular PBS solvent, indicating the compounds were released from 
the cell upon microlysis at the Single-Probe junction (Figure 23, Figure 24).   
 
4.3.3 Metabolomic Analysis  
In addition to identifying drug compound accumulation, the Single-probe/ICMP 
system was used to detect global metabolomic changes in individual K562 cells. K562 
cells were subjected to either 100 nM Taxol or vehicle (DMSO) for 24 h. A minimum of 
 
Figure 26: Quantification of intracellular gemcitabine. Scatter plot depicting the 
amount of drug (attomoles) measured at each treatment concentration for each 
gemcitabine-treated (1-h) cell. (A) T24 cells using the Single-probe method and (B) 
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20 cells for each treatment condition was analyzed using the Single-Probe/ICMP setup. 
Following the 24 h treatment, the morphology of the cells did not change, however, the 
Taxol treated group had a significant change in the metabolomic composition of the cells 
(Figure 25). A principle component analysis (PCA) was formed through taking the single 
cell mass spec (SCMS) data and subjecting it to a background removal, noise reduction, 
peak alignment, and normalization using Geena2 prior to analysis with MetaboAnalyst. 
73 metabolites were significantly changed (p < 0.05) upon drug treatment. To identify 
compounds of interest, a liquid chromatography mass spectrometry (LCMS) analysis of 
K562 lysate was performed and molecular identity was confirmed through MS/MS 
analysis. Monoglycerides (MG) and diglycerides (DG) comprised many of the 
significantly changed molecules. This data represents the capability of this method to 
both detect the amount of exogenously treated compound within the cell and perform a 
global analysis on the intracellular metabolites on a single-cell level.  
 
Table 1: Quantification of intracellular gemcitabine in T24 and K562 cells using the 
Single-Probe (T24) or Single-probe/ICMP (K562) method  
Treatment Conc. T24 (Attomole) K562 (Attomole) 
0.1 µM 13.9 ± 10.6 41.3 ± 23.5 
1 µM 27.0 ± 22.6 46.7 ± 28.2 
10 µM 42.8 ± 37.7 72.0 ± 59.5 
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4.3.4 Single-Cell Drug Quantification 
Following the development of this methodology for the detection of drug 
compounds and changes in intracellular metabolites upon drug treatment, we developed 
this technology to quantify the amount of drug compound accumulated inside single 
suspended cells. To begin this analysis, we utilized the established Single-Probe to 
quantify drug compound from the adherent bladder cancer cell line, T24. Cells were 
treated with the standard of care chemotherapeutic, gemcitabine, at either 0.1 µM, 1.0 
µM, or 10 µM for 1 h and quantified using the Single-probe  (Figure 26, Table 1). An 
internal standard of (13C, 15N-labeled) gemcitabine we prepared ([13CC8H11F215N2NO4 + 
H]+, m/z 267.0703) was added into the sampling solvent (acetonitrile with 0.1% formic 
acid). The resulting continuous flow and detection of the known concentration of internal 
standard allowed the ability to quantify the amount of detected intracellular gemcitabine 






     (Equation 4.1)  
 
A and B are the integration of the ion intensities for the target compound and 
standard, respectively, considering the internal standard concentration (c), time (t), and 
flow rate (v). This illustrated the ability to quantify the amount of gemcitabine inside 
single, adherent bladder cancer cells in vitro.  
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T24 cells were treated for 1 h with 1 µM gemcitabine and trypsinized to release 
from the solid support. The resulting suspended cells were captured and quantified for 
intracellular gemcitabine using the Single-probe/IMCP system. The intracellular amount 
of gemcitabine in 20 suspended cells was determined as 37.2 ± 9.2 attomole, which is not 
significantly different (P > 0.05) to the intracellular gemcitabine calculated in the T24 
cells while adherent using the Single probe. This result demonstrated the reproducibility 
and viability of the Single-probe/ICMP in suspension cells versus the Single-probe in 
adherent cells. Further, K562 suspension leukemia cells were treated with 0.1, 1.0, or 10 
µM gemcitabine for 1 h and subjected to the qSCMS measurement using the Single-
probe/ICMP setup (Figure 26, Table 1). The intracellular gemcitabine in individual 
K562 cells followed a similar trend to T24 cells. There is an increase of intracellular 
 
Figure 27: Gemcitabine spectra from patient isolated bladder cancer cell. Mass 
spectrum of gemcitabine and the inactive metabolite, dFdU, with 1 µM15N3-
gemcitabine from an individual cell isolated from the urine of a bladder cancer 




           
          
             
          
 
79 
gemcitabine in both the adherent T24 cells, measured with the Single-probe system, and 
the suspension K562 cells, measured with the Single-Probe/ICMP system corresponding 
to an increase in cellular dose.  
However, the increase in intracellular gemcitabine was not proportional with the 
increase in treatment condition (i.e., a 10 fold increase in treatment did not correlate with 
a 10 fold increase in intracellular amount). The 10 µM treatment correlated with a 
significant increase in intracellular gemcitabine compared to the 1 µM treatment in both 
treatments and methodologies.  
 
Figure 28: Mass spectrum of a single cell isolated from a bladder cancer patient 
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The spherical, suspended K562 cell line was also used to quantify the absolute 
concentration of intracellular gemcitabine inside each individual cell. Each cell’s 
diameter was measured by measuring the inner diameter of the cell selection probe. With 
a calculated cell volume, the concentration of gemcitabine in the K562 cells was 
determined. The intracellular concentrations of gemcitabine are significantly increased in 
a concentration dependent pattern (p < 0.05) (Table 2).  
 
Figure 29: MS/MS spectra of Gemcitabine. A) MS/MS spectra of gemcitabine 
analyzed from a single cell isolated from bladder cancer patient 1. B) MS/MS of 







A further level of validation was taken by comparing the SCMS calculated 
concentration levels of gemcitabine in K562 cells to a LCMS quantification of 
gemcitabine. LCMS is the gold standard for determining intracellular drug concentration 
by considering both the total cell count in the lysate and the estimated cellular volume 
(2.8 pL). The calculated LCMS results are the average intracellular drug concentration in 
single cells. The LCMS results showed similar comparison to the SCMS results using the 
Single-probe/ICMP setup. This further signifies the potential of this methodology for 
quantifying drug accumulation in single cells.  
 
Table 2: Concentration of intracellular gemcitabine in K562 cells using SCMS and 
LCMS. 
Treatment Conc. SCMS (µM) LCMS (µM) 
0.1 µM 10.9 ± 7.1 17.4 ± 5.0 
1 µM 17.9 ± 11.9 18.1 ± 5.8 
10 µM 37.3 ± 26.1 28.0 ± 12.6 
 
4.3.5 Clinical Single-Cell Patient Isolated Drug Quantification 
Following the validation in vitro, the Single-probe/ICMP methodology was used 
to quantify the amount of gemcitabine from non-invasively isolated cells from the urine 
of bladder cancer patients. A total of four individual bladder cancer patients were 
analyzed (Figure 30). Two of them comprised the control group (No treatment) and two 
comprised the experimental group (Gemcitabine treated). Urine was collected from the 
control group, and the cells were isolated and subjected to the Single-probe/ICMP. 
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Numerous lipid peaks were identified and correlated with previously identified PC peaks, 
signifying the ability of the method to detect intracellular metabolites form individual 
cells in vivo (Figure 28). The experimental group was administered 1000 mg/ m2 of 
gemcitabine. The urine from the treated patients were collected 1 h after the infusion. 
Gemcitabine was detected in both patients and validated though MS/MS fragmentation 
as compared to the standard solution (Figure 27, Figure 29). Gemcitabine was detected 
only from the patients who underwent chemotherapy but was not present in cells from 
the untreated patients. A limited gemcitabine quantification data set was compiled 
consisting of no more than 15 cells quantified per infusion. The amount of intracellular 
drug measured from individual cells from Patient 1 was 473 ± 188 and 1,557 ± 1004 
attomole following the second and fourth infusions, respectively. Patient 2 had a 
significantly lower amount of drug uptake than Patient 1, having 45.8 ± 39.4 and 79.4 ± 
50.9 attomole of intracellular gemcitabine following the first and second infusions, 
respectively. The measurement of intracellular drug concentration was not conducted due 
to the inability to accurately measure the dimensions of irregularly shaped patient cells. 
 













4.4 Discussion  
We’ve developed a bio-analytical method capable of quantifying the amount of 
drug accumulation inside live, single cultured cells and cells isolated from bladder cancer 
patients. The spherical physiology of the suspended cells allowed for the quantification 
of intracellular drug concentration in real time on a cell to cell basis, providing an ideal 
measurement of drug accumulation inside individual cancer cells. The Single-
Probe/ICMP system was comparable to an LCMS analysis on cellular lysate, validating 
the capability of this method on the single-cell level (Table 2).  
Single cell gemcitabine drug quantification was performed from two different 
bladder cancer patients following two infusions of gemcitabine, respectively. 
Gemcitabine is a standard of care chemotherapeutic compound for bladder cancer and is 
easily ionizable in positive ion mode making it an ideal compound for mass spectrometry 
identification. Gemcitabine (dFdC) is pro-drug, which either gets deaminated into its 
inactive metabolite, dFdU, or phosphorylated into its active metabolites dFdCMP/ 
dFdCDP/ dfFdCTP.181 dFdU was able to be identified through our Single-Probe/ICMP 
method providing another molecule to monitor for cellular accumilation, however, we 
were unable to identify any of the active phosphorylated metabolites (dFdCMP/ dFdCDP/ 
dfFdCTP), possibly due to their incorporation into DNA, ultimately leading to cellular 
toxicity.  
The Single-Probe/ICMP system is capable of detecting many different 
metabolites isolated from cells from a variety of different solutions and bodily fluids with 
little sample preparation. This technique could potentially be applied to hematological 
cancers (e.g., Leukemias/ Lymphomas) in addition to bladder cancer. Upon isolating 
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blood samples, the Single-Probe/ICMP system could quantify the amount of cancer 
therapeutics accumulating inside individual cancer cells in a real time readout, resulting 
in an optimal personalized drug monitoring method with minimal invasiveness.  
In addition to quantitative drug accumulation, the Single-Probe/ICMP system is 
able to qualitatively measure a vast degree of small molecules. This capability could be 
applied and developed for metabolomic analysis of clinically isolated cells, potentially 
following drug treatment, to identify drug cellular physiology and dynamics in situ. 
Furthermore, this technique could be used to identify certain biomarkers (i.e., intracellular 
molecules that are significantly changed upon a drug treatment) to produce another level 
of detecting compound efficacy on the single-cell level.  
 
4.5 Conclusions 
Altogether, the Single-Probe/ICMP system was developed and applied for the 
quantification of the chemotherapeutic, gemcitabine, inside individual clinically isolated 
bladder cancer cells. This methodology could be further applied for the quantification of 
other drug compounds in addition to qualitatively analyzing numerous other metabolites 









Chapter 5: Conclusions and Future Outlook 
 My dissertation research was focused on identifying and characterizing druggable 
targets and developing new bioanalytical methods translatable for use in the emerging era 
of personalized medicine. The work presented in Chapter 2 detailed my contribution to 
the discovery of a potential route for broad spectrum antiviral replication inhibition 
through a unique mechanism of targeting a host protein, rather than a viral associated 
molecule target. The discovery of that OSW-1 represses OSBP protein levels, leading to 
a prophylactic antiviral response, could lead to a broad-spectrum treatment of pathogenic 
viral infections. Although the mechanism of long-term repression was not identified, the 
OSW-1-induced repression of OSBP is not due to the obvious potential cellular 
mechanisms such as residual OSW-1 compound, calpain activity, proteasome 
degradation, autophagy, or transcription inhibition.107 Furthermore, the OSW-1-induced 
reduction of OSBP is specific to OSBP.108 
 Future work needs to be conducted into identification of the biological mechanism 
into the repression of the OSBP protein. Such a finding could have significant impacts 
into drug development for a wide range diseases. Such a mechanism could be a miRNA 
mediated targeted repression of the OSBP mRNA transcript, although the how binding 
of a small molecule to a protein (i.e., OSW-1 binding to OSBP) would initiate such a 
response, is unknown. The discovery of the mechanism, however, has obvious benefits 
to human health and drug development.  
 My work in studying ORP4 as a potential precision target in ovarian cancer 
(Chapter 3) showed the potential of the OSW-1-compound as personalized medicine. 
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We demonstrated that the ORP4 expression was ubiquitous among all four ovarian cancer 
cell lines tested in both a 2D and 3D models. The OSW-1 compound showed superior 
antiproliferative activity compared to the ovarian standard of care compounds paclitaxel 
and cisplatin in both ovarian monolayer and spheroid models.  The cytotoxicity of the 
OSW-1 compound correlated to the degradation of the ORP4L protein, supporting the 
claim that the ORP4 protein is the cytotoxic target, rather than the OSBP protein. Of 
important significance, the OSW-1 compound was significantly more potent in the 
absences of extracellular lipids and attenuated by the addition of exogenous cholesterol. 
This phenomenon could potentially be exploited for the precision targeting of tumors, 
which are nutrient deprived. In this model, the targeting of both OSBP and ORP4 are 
additive in cytotoxic effects due to the cholesterol depletion in tumors. If true, this should 
make normal tissue with adequate cholesterol less responsive to OSW-1 compounds.  
 More research is needed to validate that the significant increase in cytotoxicity 
specifically to the OSW-1 compound is caused by the degradation of OSBP, and if it is, 
needs to be translated to an in vivo model.  The implications of this research are profound, 
as it identifies biological targets to produce an ideal, precision medicine that targets the 
cancer cells, specifically tumors, with a large therapeutic window with efficacy against a 
broad range of cancers.  
 Beyond studying new druggable cellular targets, my dissertation research also 
encompassed new bioanalytical technology to measure drug compounds in cancer cells. 
This application of single cell mass spectrometry in drug quantification could lead to 
personalization of drug administration in way not currently possible. We have developed 
the Single-probe/ICMP qSCMS system to determine the concentration of 
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chemotherapeutic drugs in single suspended cells in vitro, and then used this system to 
quantify the amount of intracellular gemcitabine in cells isolated from bladder cancer 
patients. The Single-probe/ICMP qSCMS method can be further developed to quantify 
the amount of many different intracellular molecules of interest (e.g., drug compounds, 
lipids, metabolites, etc.) and to discriminate cell types based on metabolomic features of 
individual clinical cells, such as normal vs. cancerous cells. This method can potentially 
be used to measure therapeutically informative levels of drug compounds within cells in 
order to develop precision drug monitoring and administration. Single-cell quantification 
of drug compounds isolated from non-invasive patient samples is a major advancement 
for the development of single cell pharmacology. Single cell pharmacology could lead to 
understanding the action of drugs on the level of individual disease cells and provide a 
new paradigm in the development and better administration of drug compounds in 
patients. 
 Further development is still needed on the technology for it be incorporated into 
a clinical setting. Intensive validation and precision need to be optimized and 
methodology for discriminating cells in an efficient method needs to be implemented. 
One such method could be a FACS methodology through flow cytometry to discriminate 
cancer from non-cancerous cells. Furthermore, if blood samples are used rather than 
epithelial bladder cancers, a spherical cell output could be obtained and sorted through 
FACS. This would produce an ideal cell population to use our technology to quantify the 
cellular drug concentration in individual cancer cells compared to normal cells to produce 
a real-time output reading of drug monitoring and personalized chemotherapeutic 
administration regiment.  
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Figure 38: Spheroid Cytotoxicity and Protein levels. A) Spheroid images of SKOV-
3 and OVCAR-8 treated with the provided concentration of compound at the 
provided times. B) Protein quantification of OSBP and ORP4L spheroid (3D) levels 



























































































































































































Figure 48: Mass spectrum of gemcitabine and 15N3-gemcitabine. (A) Spectra from a single T24 cell 













Figure 49: Spectra of Gemcitabine depicting the limit of quantification (LOQ) utilizing the single 





             
           
 
 
